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  Adipose tissue is traditionally regarded as a source of energy storage and 
cushion for skeletal functions.  Soft tissue injuries take place in war and peace time, as a 
result of tumor resection such as breast cancer, and in rare disorders such as 
lipoatrophy.  Adipose tissue reconstruction is one of the key challenges in medicine.  
Here we report the robust differentiation of human adipose derived stem cells using a 
small molecule into adipocytes. This thesis describes the biological effects and actions of 
novel unknown small-molecule inhibitor of BMP signaling—Pyrintegrin, which was 
previously found to promote human embryonic stem cells survival.  The overall 
objective of this thesis is to test the hypothesis that this novel drug, Pyrintegrin 
treatment will induce, promote and accelerate adipogenic differentiation of stem cells in 
vitro and in vivo. We found that Pyrintegrin promotes the adipogenesis-dependent 
 
 
transcriptional changes of multiple gene products involved in the adipogenic process, 
including peroxisome proliferator-activated receptor (PPARγ), CCAAT/enhancer-
binding protein α (C/EBPα), adiponectin and leptin secretion, and total triglyceride 
secretion. When transplanted into mice, Pyrintegrin treated adipose cells/progenitors 
gave rise to ectopic fat pads with the morphological and functional characteristics of 
white adipose tissue. This was further confirmed by higher expression of human 
PPARγ gene in Pyrintegrin treated cells group than any other group. We further tested 
the presence of human nuclear staining that confirmed the presence of human cells in 
all the transplanted groups. However, the number of positive human cells was 
substantially low in all the groups, which was likely due to transplanted cell death 
because of lack of vascularization. Hence, we further tested the Pyrintegrin adsorbed 
scaffolds capacity to regenerate better soft tissue compared to Ptn-free scaffold. We 
found that Ptn adsorbed scaffolds was positive for adipocytes as evident by positive Oil 
Red O staining.  
We further investigated the signaling mechanism of Pyrintegrin. Using a human 
PPARγ reporter assay system, based on non-human mammalian cells engineered to 
express human PPARγ protein, we found that Pyrintegrin is not a PPARγ agonist as 
witnessed by lack of any luciferase activity. In contrast, Rosiglitazone, a known PPARγ 
agonist demonstrated significant amount of luciferase activity in these reporter cells. 
We also found that Pyrintegrin selectively inhibits the BMP pathway and thus blocks 
 
 
BMP-mediated SMAD1/5 phosphorylation, target gene transcription and osteogenic 
differentiation.  In vitro studies showed that Pyrintegrin inhibited the differentiation of 
stem cells into putative osteoblasts, as evident by decreased alizarin red staining. A 
striking finding was that Pyrintegrin up regulated markers of adipogenesis and 
stimulated lipid droplets accumulation in stem cells undergoing osteoblastic 
differentiation in vitro. This came at the expense of down regulating markers of 
osteogenesis and osteoblastic differentiation of stem cells, as compared to the cells 
undergoing osteogenic differentiation in the absence of the drug treatment.   
 These findings show that the novel small-molecule Pyrintegrin is a potent 






TABLE OF CONTENTS 
CHAPTER 1. BACKGROUND AND MOTIVATION ............................................................ 1 
1.1 INTRODUCTION .................................................................................................................. 1 
1.1.1 Biology of Adipose tissue ........................................................................................... 2 
1.1.2 Derivation of adipocytes from stem cells in vitro .................................................... 9 
1.1.2.1 White adipocytes ................................................................................................... 9 
1.1.2.2 Transcription factors involved in adipogenesis ............................................. 13 
1.1.2.3 Molecular signature and localization of adipocyte precursors .................... 15 
1.1.2.4 Signaling Pathways involved in adipocyte differentiation .......................... 16 
1.1.3 Small molecules for adipogenesis ........................................................................... 20 
1.1.4. Balance between Osteogenesis and Adipogenesis .............................................. 22 
1.2 PURPOSE OF STUDY ......................................................................................................... 26 
1.2.1 Aim 1: To determine the effect of Pyrintegrin treatment in vitro ....................... 26 
1.2.2 Aim 2: To test the effect of the Pyrintegrin treatment in vivo ............................. 27 
1.2.3 Aim 3: To determine the signaling mechanism of Pyrintegrin ........................... 28 
1.3 SIGNIFICANCE AND ORGANIZATION ....................................................................... 30 
CHAPTER 2. PYRINTEGRIN PROMOTES STEM CELL ADIPOGENIC 
DIFFERENTIATION .................................................................................................................. 33 
2.1 INTRODUCTION ................................................................................................................ 33 





2.2.1 Human adipose derived stem cell isolation and expansion ................................ 37 
2.2.2 Treatment with Pyrintegrin...................................................................................... 39 
2.2.3 Multi-lineage differentiation potential of Pyrintegrin treated cells ................... 39 
2.2.4 Real Time‐Polymerase Chain Reaction (RT-PCR) analysis ................................. 41 
2.2.5 Lipid staining of adipogenic differentiated cells .................................................. 42 
2.2.6 Biochemical assays for adipogenic markers .......................................................... 43 
2.2.7 Statistical analysis ...................................................................................................... 44 
2.3 RESULTS ............................................................................................................................... 45 
2.3.1 Regulation of adipogenic specific markers ............................................................ 45 
2.3.2 Optimal dose of Pyrintegrin to induce adipogenic differentiation .................... 47 
2.3.3 Time course analysis of adipogenic markers ......................................................... 49 
2.3.4 Lipid staining of differentiated cells ....................................................................... 51 
2.3.5 Directing stem cell fate .............................................................................................. 53 
2.3.6 Secretion of adipocytokines ..................................................................................... 55 
2.3.7 Secretion of total triglycerides and glycerol .......................................................... 57 
2.4 CONCLUSION ..................................................................................................................... 59 
CHAPTER 3. PYRINTEGRIN PROMOTES FAT FORMATION IN VIVO ........................ 61 
3.1 INTRODUCTION ................................................................................................................ 61 
3.2 MATERIALS AND METHODS ......................................................................................... 64 





3.2.2 Treatment of hADSCs with adipogenic supplements .......................................... 64 
3.2.3 In vivo subcutaneous scaffold implantation ........................................................... 65 
3.2.4 Pyrintegrin infusion within the scaffold ................................................................ 66 
3.2.5 In vivo fat pad scaffold implantation ...................................................................... 67 
3.2.6 Histological analysis .................................................................................................. 68 
3.2.7 Immunohistochemistry ............................................................................................. 68 
3.2.8 RNA extraction and reverse transcription polymerase chain reaction .............. 69 
3.3 RESULTS ............................................................................................................................... 70 
3.3.1 De novo formation of adipose tissue by Pyrintegrin treatment cells .................. 70 
3.3.2 Detection of human adipocyte specific gene in scaffolds .................................... 73 
3.3.3 Detection of transplanted human cells in scaffolds .............................................. 76 
3.3.4 De novo formation of adipose tissue in Pyrintegrin infused scaffold ................. 78 
3.4 Conclusion ............................................................................................................................ 80 
CHAPTER 4. SIGNALING MECHANISM OF PYRINTEGRIN ......................................... 83 
4.1 INTRODUCTION ................................................................................................................ 83 
4.2 Materials and methods ........................................................................................................ 87 
4.2.1 Cell culture .................................................................................................................. 87 
4.2.2 Multi-lineage differentiation .................................................................................... 87 
4.2.3 Human PPARγ Reporter Assay Study ................................................................... 87 





4.2.5 Immunoblot analysis of BMP and TGF-β–responsive SMAD phosphorylation
 ............................................................................................................................................... 89 
4.2.6 Real Time‐Polymerase Chain Reaction (RT-PCR) analysis ................................. 90 
4.2.7 Alizarin Red S staining ............................................................................................. 91 
4.2.8 Lipid staining ............................................................................................................. 91 
4.2.9 Dexamethasone dose treatment analysis ............................................................... 92 
4.2.10 Statistics ..................................................................................................................... 92 
4.3 RESULTS ............................................................................................................................... 93 
4.3.1 Is Pyrintegrin a PPARγ agonist? ............................................................................. 93 
4.3.2 Signaling mechanism of Pyrintegrin....................................................................... 95 
4.3.3 Pyrintegrin inhibits SMAD-dependent BMP signals ........................................... 97 
4.3.4 Pyrintegrin inhibits osteogenic gene expression in osteogenic differentiated 
hADSCs .............................................................................................................................. 100 
4.3.5 Pyrintegrin inhibits osteoblast differentiation .................................................... 104 
4.3.6 Pyrintegrin promotes lipid accumulation in osteogenic differentiated hADSCs
 ............................................................................................................................................. 106 
4.3.7 Dexamethasone and Pyrintegrin combination promotes lipid accumulation in 
osteogenic differentiated hADSCs ................................................................................. 108 
4.4 CONCLUSION ................................................................................................................... 110 





5.1 SUMMARY ........................................................................................ …………………     113 
5.2 FUTURE DIRECTIONS ..................................................................................................... 117 
5.2.1 Pyrintegrin for treatment of obesity and diabetes .............................................. 117 
5.2.2 Pyrintegrin for treatment of bone disorders ........................................................ 119 




















LIST OF FIGURES AND TABLES 
 
Figure 1-1:  White adipose distribution in the body. Adopted from (Cook and Cowan 
2008) ............................................................................................................................................... 3 
Figure 1-2: Adipose derived stem cells are undifferentiated non-hematopoietic stem 
cells capable to transform themselves into a number of cell types, especially bone cells 
(osteoblasts), cells forming cartilage (chondrocytes), adipose tissue (adipocytes), and 
others. Adopted from Articell company website. ................................................................... 5 
Figure 1-3: A schematic showing generation of myeloid-derived adipocyte progenitor 
cells from hematopoietic stem cells in bone marrow (BM). The myeloid-derived 
progenitors regulates the cell towards becoming bone marrow progenitor (BMP) 
derived adipocyte, where they lose hematopoietic marker expression. Adopted from 
(Majka et al. 2010)......................................................................................................................... 6 
Table 1: List of human tissue derived stem cells that can undergo adipogenic 
differentiation in vitro ................................................................................................................ 10 
Figure 1-4: Ceiling culture of mature fat tissue. Mature white fat tissue is chopped into 
small pieces and centrifuged. Sediments are not used in this culture. Floating tissue 
layer was incubated in culture flasks completely filled with medium. The mature fat 
cells floated to the top of the medium and adhered to the top ceiling surface of the flask. 





observation. Inset: histology of the floated tissue which consists for the most part of 
unilocular fat cells with a few stromal-vascular cells. Scale bar is 100 µm. Adopted from 
(Sugihara et al. 1986). ................................................................................................................. 12 
Figure 1-5: Mesenchymal stem cells in bone marrow (BM) give rise to osteoblastic cells 
and adipocytes. Under homeostasis, a balance in hematopoiesis is maintained by 
support from osteoblastic cells and suppression of adipocytes. But if the BM is exposed 
to stress or becomes aged, an imbalance in adipocytes suppresses hematopoiesis. 
Adopted from (Sugimura and Li 2010). .................................................................................. 25 
Figure 1-6: Chemical structure of Pyrintegrin (Ptn). Adopted from (Xu et al. 2010). ...... 30 
Figure 1-7: Common types of plastic and reconstructive surgery. Treat disfiguring Facial 
wrinkles and sagging due to aging or vanity (A), Mastectomy or Lumpectomy (B) and 
injuries and conditions (C). ...................................................................................................... 32 
Figure 2-1: Regulation of stem cell differentiation specific markers. Relative gene 
expression of mRNA markers for adipogenesis was quantified after 4 days in hADSCs 
culture treated with Control, ODM, ODM+Ptn, CDM, CDM+Ptn, ADM and ADM 
containing Pyrintegrin. The addition of Ptn at 2 µM concentration to any of the 
differentiation medium significantly increased the expression of adipogenic specific 
gene, PPARγ as compared to hADSCs treated with differentiated medium alone. ........ 46 
Figure 2-2: Optimal dose of Pyrintegrin for inducing adipogenic differentiation in 





adipogenesis was quantified in hADSCs culture treated with Control, ADM and ADM 
containing varying doses of Pyrintegrin. By 4 days, PPARγ and C/EBPα mRNA 
expressions were significantly increased only in 2 µM Pyrintegrin treatment group in 
comparison with control and ADM treated group. At 5 and 10 µM concentration, 
Pyrintegrin drug was not effective in up-regulating both PPARγ and C/EBPα 
expression as compared to 2 µM treated Pyrintegrin group. .............................................. 48 
Figure 2‐3: Time course analysis of adipogenic markers. Relative gene expression of 
mRNA markers for adipogenesis was quantified in hADSCs culture treated with 
Control, ADM and ADM containing 2 µM of Pyrintegrin. Over the period of 28 days, 
Pyrintegrin treatment maintained a higher up regulation of both PPARγ (a) and 
C/EBPα (b) gene expression as compared to control and ADM treated group. ............... 50 
Figure 2‐4: Human adipose derived stem cells (hADSCs) undergo lipid accumulation 
upon differentiation treatment. Lipid accumulation was assessed for adipogenesis 
differentiation in hADSCs culture treated with ADM (A and A1) and ADM+Ptn (B and 
B1) treated medium for 4 wks.  Using a fluorescent lipid staining dye, we found that 
addition of 2 µM of Ptn to the ADM markedly increased the number of visible lipid 
droplets compared to hADSCs differentiated in ADM as evidenced by more lipid 
staining. Scale bar: 100 µm. ...................................................................................................... 51 
Figure 2‐5: Optimal dose of Pyrintegrin for inducing adipogenic differentiation in 





in hADSCs culture treated with Control, Control containing varying doses of 
Pyrintegrin and ADM medium. By 4 days, PPARγ mRNA expression was significantly 
increased in both 2 and 10 µM Pyrintegrin treatment group in comparison with control 
group. But C/EBPα mRNA expression did not increase in any of the Pyrintegrin 
treatment group as compared to ADM group. ...................................................................... 54 
Figure 2‐6: Secretion of Adipocytokines. Absolute release profile of adipocytokines was 
quantified in hADSCs culture treated with Control, ADM and ADM containing 2 µM of 
Pyrintegrin. At both 2 and 4 weeks, Pyrintegrin treatment maintained a higher release 
profile of both Adiponectin (a) and Leptin (b) cytokines as compared to control and 
ADM treated group. .................................................................................................................. 56 
Figure 2‐7: Secretion of fatty acids. Absolute release profile of glycerol and total 
triglycerides was quantified in hADSCs culture treated with Control, ADM and ADM 
containing 2 µM of Pyrintegrin. At both 2 and 4 weeks, Pyrintegrin treatment 
maintained a higher release profile of both Glycerol (a) and Total triglycerides (b) as 
compared to control and ADM treated group. ...................................................................... 58 
Figure 3‐1: In vivo adipogenesis induced by tissue-engineered PCL constructs 
encapsulating human adipose derived stem cells (hADSCs) derived adipogenic cells. 
Representative images of Scaffold (A and A1), scaffold encapsulating hADSCs treated 
in control medium, Scaffold + cells (B and B1), scaffold encapsulating hADSCs treated 





hADSCs treated with ADM containing 2 µM of Pyrintegrin, Scaffold + ADM + Ptn 
treated cells (D and D1) implanted in the dorsum of immunodeficient mice for 4 weeks. 
Scaffold and Scaffold + cells group demonstrate no fat deposition as evident by negative 
reaction to Oil Red O staining. On the other hand, Scaffold + ADM and Scaffold + ADM 
+ Ptn treated group exhibited positive oil red O staining as evident by small lipid 
droplets (white arrowheads). Of all the groups, Scaffold + ADM + Ptn treated group 
formed a better adipogenic tissue than any other group as evidenced by unilocular fat 
droplets (black arrowheads), characteristic of mature fat cells.  All the implanted 
constructs exhibit characteristic mouse host cell invasion. PCL scaffold strand is also 
stained red by Oil Red O dye. Scale bar: 100 µm. ................................................................. 71 
Figure 3‐2: RT-PCR analysis showing expression of human and mouse adipocyte-
specific gene PPARγ.  The constructs Scaffold (A), scaffold encapsulating hADSCs 
treated in control medium, Scaffold + cells (B), scaffold encapsulating hADSCs treated 
with ADM, Scaffold + ADM treated cells (C), and scaffold encapsulating hADSCs 
treated with ADM containing 2 µM of Pyrintegrin, Scaffold + ADM + Ptn treated cells 
(D) were harvested from the dorsum of immunodeficient mice after 4 weeks. Of all the 
groups, Scaffold + ADM + Ptn treated group showed higher expression of human 
PPARγ gene than any other groups tested. All the implanted constructs exhibit 






Figure 3‐3: Human Nuclear staining (HNA) of in vivo implanted constructs. 
Representative images of Scaffold (A), scaffold encapsulating hADSCs treated in control 
medium, Scaffold+cells (B), scaffold encapsulating hADSCs treated with ADM, 
Scaffold+ADM treated cells (C), and scaffold encapsulating hADSCs treated with ADM 
containing 2 µM of Pyrintegrin, Scaffold+ADM+Ptn treated cells (D) implanted in the 
dorsum of immunodeficient mice for 4 weeks. Positive human nuclear staining was 
observed in all the constructs except Scaffold group as evident by green fluoresce, 
whereas blue fluoresce represents DAPI staining that stains the nucleus of all the cells, 
transplanted as well as host cells. Scale bar: 100 µm……………………………………77 
Figure 3‐4: In vivo adipogenesis induced by tissue-engineered PCL constructs infused 
with collagen gel with or without Pyrintegrin. (A) Scaffold is implanted within the fat 
pad of C57BL/6 mice. Representative images of Scaffold (B) and scaffold encapsulating 
Pyrintegrin, Scaffold + Ptn (C) implanted in the fat pad of C57BL/6 mice for 4 weeks. 
Scaffold + Ptn group formed a better adipogenic tissue than Scaffold group as exhibited 
by positive oil red O staining (white arrowheads). PCL scaffold strand is also stained 
red by Oil Red O dye. Scale bar: 100 µm. ............................................................................... 79 
Figure 4-1: Schematic drawing showing the cellular mechanisms of BMP-induced 
osteoinduction in a mesenchymal bone marrow stem cell. 1 = Type I and Type II BMP 
homodimer receptors exist independently in the cell membrane.  2 = Upon activation by 





I BMP receptors activate the intracellular messengers (SMADs). 4 = Activated SMADs 
localize across the nuclear membrane after association with activated Smad-4, a critical 
cofactor. 5 = Once within the nucleus, SMAD proteins induce specific gene expression. 
Adopted from (Walker and Wright 2002). ............................................................................. 86 
Figure 4‐2: Human PPARγ luciferase reporter assay system. Rosiglitazone, a known 
PPARγ agonist, significantly up regulated PPARγ luciferase activity at 0.5 µM 
concentration (positive control).  Whereas, culture Pyrintegrin failed to up regulate 
PPARγ luciferase activity at any of the tested concentration. Hence, Pyrintegrin is not a 
PPARγ agonist. ........................................................................................................................... 94 
Figure 4‐3: Pyrintegrin inhibits BMP signaling pathway. Phosphorylation of SMAD1/5/8 
(a) and p44/42 MAPK (b) in hADSCs detected by immunoblot after pretreatment with 
Control, ADM, ADM+Ptn and Control+Ptn medium for 1 hr (a).  Equivalent protein 
loading was confirmed by detection of total SMAD1 and β-Actin. ................................... 96 
Figure 4‐4: Pyrintegrin inhibits BMP-mediated activation of SMAD. (a) Phosphorylation 
of SMAD1/5 in hADSCs detected by immunoblot after treatment with BMP4 and 
Pyrintergin for 1 hr. Equivalent protein loading was confirmed by detection of total 
SMAD1 and β-Actin. (b) Phosphorylation of SMAD2 in hADSCs after treatment with 
TGFβ1 and Pyrintegrin for 1 hr. Treatment with Pyrintegrin (0.1-20 µM) did not inhibit 
TGFβ1-mediated activation of SMAD2.  (c) Phosphorylation of MAPK p38 in NIH/3T3 





Figure 4‐5: Pyrintegrin inhibits osteogenic specific genes in osteogenic-mediated 
differentiation of hADSCs. Relative quantification of human osteogenic RunX2 (a) and 
Osx (b) and adipogenic markers, PPARγ (c) and CEBPα (d) gene expression in hADSCs 
culture treated with Control, ODM and ODM containing 2 µM of Pyrintegrin 
(ODM+Ptn). ODM+Ptn showed a significant down regulation in osteogenic gene 
expression and a significant up regulation of adipogenic specific genes than ODM 
group throughout the tested time period. ............................................................................ 102 
Figure 4‐6: Pyrintegrin inhibits osteoblast differentiation of hADSCs in vitro. Human 
ADSCs were induced to differentiate for 21 days in osteogenic differentiation medium 
(ODM) (A and A1), ODM containing 2 µM of Pyrintegrin (ODM+Ptn) (B and B1). The 
addition of Ptn to the osteogenic differentiation medium significantly inhibited the 
production of mineralized nodules as seen by less Alizarin Red S staining compared to 
ODM alone group. Scale bar: 100 µm. .................................................................................. 105 
Figure 4‐7: Pyrintegrin promotes lipid formation in osteogenic-mediated differentiation 
of hADSCs. Fluorescent red lipid staining in hADSCs culture treated with ODM (A, D 
and G), ODM containing 2 µM of Pyrintegrin (ODM+Ptn) (B, E and H) and control 
medium containing 2 µM of Pyrintegrin (Ptn) (C, F and I). Only ODM+Ptn group 
showed an accumulation of lipids during the tested 7 (B), 14 (E) and 21 (H) days. Scale 
bar: 100 µm. ............................................................................................................................... 107 





formation. hADSCs culture are treated with 2 µM of Pyrintegrin and varying dose of 
Dex 0.1 µM (A, A1 and A2), 1 µM (B, B1 and B2) and 10 µM (C, C1 and C2) for 21 days. 
Presence of Dex and not its concentration is important for lipid accumulation in Ptn 
treated hADSCs. Scale bar: 100 µm. ...................................................................................... 109 
Figure 5-1: Role of PPARγ pathway on osteogenesis. Bone homeostasis is maintained by 
the balance between osteoblastic bone formation and osteoclastic bone resorption. An 
imbalance in this homeostasis is associated with osteoporosis. The PPARγ pathway 
influences adipocyte differentiation from mesenchymal progenitors at the cost of 
inhibiting osteoblast differentiation. Adopted from (Pei and Tontonoz 2004). This new 
finding raises the possibility of interrupting the PPARγ pathway for the treatment of 













No one can argue that one of the most important persons during the PhD program is 
your advisor. It is very critical to choose the right mentor and in this regard, I deeply 
thank my advisor Dr. Jeremy J. Mao for his guidance and mentorship during my 
doctoral studies. He is not only a very generous, kind and nice mentor but also an 
enthusiastic, confident but humble, and sometimes propulsive scientist. He gave me the 
freedom to explore new ideas and pursue them, which helped me gain immense 
confidence, for which I am very thankful to him.    
In addition, I would like to thank my dissertation committee members, Drs. 
Helen Lu, Gordana Vunjak-Novakovic, Samuel Sia, Lance Kam and Igor Matushansky, 
for their insightful advice and suggestions, and for having lively and exciting 
discussion about my thesis study. I would also like to acknowledge Dr. Srikala 
Raghavan for their guidance and support.  
I would also like to thank all of my lab members, Dr. Mo Chen, Dr. Millie 
Embree, Dr. Eduardo Moioli, Dr. Chang Lee, Dr. Kimi Kong, Dr. Hemin Nie, Dr. 
Chuanyong Lu, Dr. Rujing Yang, Avital Mendelson, Dr. Jiang, and Nan. I would like to 
express my sincere gratitude to Drs. Mo Chen and Millie Embree for their guidance, 
support and continuous encouragement. I would also like to specially thank Dr. 
Takahiro Suzuki for his continuous help during my PhD program. I would also like to 





administrative support, and all the dental, graduate and undergraduate research interns 
I have mentored for their hard working and research achievements. 
Most importantly, I want to express my special thanks to my one and only life 
companion, Kaushal Shah, and my family members, my life mentor and best dad 
Shailesh Shah, lovely mother Pratibha Shah, brother Monik Shah, sister-in-law Khyati 
Shah and my two adorable nephews, Dhairya and Rushi Shah for their full support, 
encouragement, trust, love and prayer, regardless of circumstance. Lastly, I want to 
thank some of very special friends, Pranjali and Dipendra Chattopadhyay, Shilpa and 
Sandeep Joshi, Renold Rodriguez, and Anand Rane and my dearest cousins, Nishant 
Shah and Binal Shah, who have been my side almost all my life and have supported me 


























Namo Loe Savva-sahunam 
 
Eso Panch Namokaro 
Savva-pavappanasano 
Manglananch Savvesim 










CHAPTER 1. BACKGROUND AND MOTIVATION 
1.1 INTRODUCTION 
Patients with soft tissue trauma, such as breast cancer, facial and skeletal injuries have 
to undergo a reconstructive surgery. For patients undergoing lumpectomy, mastectomy 
or augmentation mammoplasty, synthetic breast implants remain the current choice for 
restoration of breast morphology. However, silicone gel and saline implants suffer from 
capsular contracture, dislocation, potential leakage, extrusion, and benign calcification 
(Jenkins, Friedman and von Recum 1996, Shiffman 1994). Substantial pain and/or tissue 
deformation may result from these adverse effects, necessitating secondary surgeries, 
including capsulotomy or capsulectomy. Alternatively for breast reconstruction, a tissue 
flap, consisting of skin, fat and muscle is surgically harvested from either transverse 
rectus abdominus muscle (TRAM), latissimus dorsi flap, deep interior epigastric 
perforator flap (DIEP), or superior gluteal perforator flap (Arnez et al. 1999b, Arnez et 
al. 1999a, Moioli et al. 2010, Van Zele and Heymans 2004) to be inserted at the surgery 
site. For patients with facial trauma, fat grafting is the current surgical gold standard 
technique (Mao et al. 2010), although in a recent study fat transfer was also utilized for 
breast cancer patients (Rubin et al. 2012).  However, autologous fat tissue grafting 
suffers from donor-site morbidity (Alster and West 2000, Beahm, Walton and Patrick 





postsurgical volume reduction and contour changes, and necrosis of the transplanted 
tissue (Chajchir and Benzaquen 1986, de la Fuente and Tavora 1988, Matsudo and 
Toledo 1988, Moioli et al. 2010, Niechajev and Sevcuk 1994). On the other hand, 
allografts and xenografts fat transfer are associated with severe complications such as 
pathogen transmission, immune rejection, and suboptimal integration (Butler and 
Awad 1999, Erol and Spira 1990, Kononas et al. 1993, Eppley 1999, Zuk et al. 2001, Hart 
2003, Mao et al. 2010). Hence, the need for a bioengineered soft tissue for reconstruction 
surgeries prevails. Adipose tissue engineering involves the use of a three dimensional 
(3D) scaffold that forms the initial framework for tissue formation seeded with patient’s 
stem cells and growth factors to potentiate cell differentiation and vascularization. 
Numerous sources of stem cells for soft tissue engineering have been utilized; bone 
marrow, abdominal fat, ligament etc. as listed in Table 1 below. On the other hand, 
choice of scaffold material varies from soft gel, Fibrin to hard material, poly-
caprolactone (PCL).  Using this combination, the goal is to form a tissue which is very 
similar to the native tissue both in composition and function.  
 
1.1.1 Biology of Adipose tissue 
In humans, adipose tissue is present in several locations; breast, surrounding internal 
organs (visceral adipose tissue, VAT), beneath the skin (subcutaneous adipose tissue, 






Figure 1-1:  White adipose distribution in the body. Adopted from (Cook and Cowan 
2008) 
 
Depending on its location, the fat has different functions. The subcutaneous fat is 
mainly responsible for providing energy by burning the fat that is stored within the cell 
in the form of lipids. Visceral adipose tissue is a critical regulator of glucose and fat 
metabolism because of its association with the hepatic portal venous system (Tran and 





tissue stem cells and preadipocytes are more potent in becoming adipocytes. For 
example, same donor derived abdominal subcutaneous stem cells have been found to 
be more adipogenic than mesenteric and omentum visceral derived stem cells 
(Tchkonia et al. 2002).  
 Adipose tissue primarily consists of stem/progenitor cells, adipocyte lineage-
committed preadipocytes, mature adipocytes, fibroblasts, endothelial cells, 
macrophages, and smooth muscle cells. These progenitor cells localize along the blood 
vessels (Cai et al. 2011, Tang et al. 2008) forming a regional fat depot, and give rise to a 
resident self-renewing population of progenitors, preadipocytes (Majka et al. 2010). 
These preadipocytes and progenitors cells can be isolated from fat stroma and 
differentiated into multilineages in vitro (endothelial, adipose, cartilage, and bone) 
(Guilak et al. 2006). These progenitor cells are present throughout our life to replace 
dying adipocytes and for expansion of adipose tissue during times of excess energy 
availability. In humans, adipocyte turnover is approximately 10% every year (Spalding 
et al. 2008). A paracrine negative-feedback loop exists within the adipose tissue that 
inhibits progenitors to become preadipocytes and preadipocytes to become mature 
adipocytes (Janke et al. 2002).  
 However, the identity of these adipocyte progenitor cells remains unclear 
because of the heterogeneous population of cells within the adipose stroma and absence 





cells. The most prevalent paradigm in adipose biology is that adipose tissue is of 
mesodermal origin and adipose tissue progenitor cells can be differentiated into 
different mesenchymal cell types (Timper et al. 2006, Seo et al. 2005, Safford et al. 2002, 
Planat-Benard et al. 2004, Ogawa et al. 2004, Li et al. 2011).  
 
 
Figure 1-2: Adipose derived stem cells are undifferentiated non-hematopoietic stem 
cells capable to transform themselves into a number of cell types, especially bone cells 
(osteoblasts), cells forming cartilage (chondrocytes), adipose tissue (adipocytes), and 
others. Adopted from Articell company website.  





However, another study revealed that the bone marrow progenitor-derived 
adipocytes arise from hematopoietic cells of the myeloid lineage rather than 




Figure 1-3: A schematic showing generation of myeloid-derived adipocyte progenitor 
cells from hematopoietic stem cells in bone marrow (BM). The myeloid-derived 
progenitors regulates the cell towards becoming bone marrow progenitor (BMP) 
derived adipocyte, where they lose hematopoietic marker expression. Adopted from 
(Majka et al. 2010) 
 
This finding was confirmed by using mice in which LacZ expression was 
restricted to the myeloid lineage cells. A significant number of LacZ+ adipocytes were 





the adipose tissue. Non-LacZ+ adipocytes were also present in these mice suggesting 
that not all adipocytes are derived from myeloid progenitors. Ogawa and coworkers 
also reported the generation of adipocytes from clonally derived marrow hematopoietic 
stem cells in transplant in vivo studies (Sera et al. 2009). 
 There are two types of fat cells, white and brown. White adipocytes are the 
dominant fat cells in majority of the adipose depots found in human body. A mature 
white adipocyte has a single large lipid droplet (unilocular appearance) and its primary 
function is fat storage in the form of lipid, regulate and release energy in response to 
hormonal stimulation. Brown adipocytes have a more limited distribution in the body, 
along the supraclavicular fossa of adult humans  (Lee et al. 2011) and behind the 
sternum. A brown adipocyte contains several smaller lipid droplets (multilocular 
appearance) and its primary function is to oxidize fatty acids for heat production 
(Majka et al. 2010).  
 Our understanding of adipose tissue as a mere energy reservoir has been proven 
wrong in the last couple of decades.  Adipose tissue is now also recognized as a 
metabolically active endocrine organ that plays key roles in energy homeostasis, our 
eating behavior, energy expenditure, insulin sensitivity, and inflammation. Energy 
homeostasis and its expenditure are manifested through the regulated storage of fat and 
breakdown and release of fatty acids into the circulation. Adipocytes also produce 





tumor necrosis factorα, (TNFα), angiogenic protein such as vascular endothelial growth 
factor (VEGF) and adipocytokines such as leptin, which suppresses appetite and 
increases metabolic rate and fat oxidation (Pelleymounter et al. 1995), and adiponectin, 
which enhances insulin sensitivity and diminishes inflammation (Brochu-Gaudreau et 
al. 2010). Although adipocytes can be induced to produce almost all known 
adipocytokines, preadipocytes, as well as macrophages and endothelial cells resident in 
adipose tissue also contribute to adipocytokine production. Adipose tissue derived 
endothelial cells secrete soluble adipogenic factors that promote preadipocytes 
proliferation (Hutley et al. 2001). 
 The differential impact of visceral versus subcutaneous fat on health and the 
distinction between white and brown fat highlight an important concept in adipose 
tissue biology, namely, that fat in different body locations exhibits distinct features and 
functional characteristics. These regional differences in adipose tissue composition and 
function include variations in depot cell populations (endothelial cells, myeloid cells, 
lymphocytes, etc.), differences in innervation and the microvasculature of each depot 
(Tchkonia et al. 2007). In addition, different regional depots harbor distinct adipocyte 
populations. Differences between adipocytes from visceral and subcutaneous depots 
have been recognized for many years. For example, VAT adipocytes exhibit high rate of 
fatty acid turnover and lipolysis, and are less responsive to the antilipolytic effects of 





circulation than SAT adipocytes (Majka et al. 2010). Also, VAT adipocytes secrete more 
interleukin-6 (IL-6), an inflammatory cytokine that suppresses insulin responsiveness 
but less adiponectin and leptin than SAT fat cells (Bahceci et al. 2007). Such differences 
might provide us with a link between increased visceral adiposity and insulin resistance 
and inflammation associates with obesity (Majka et al. 2010). Despite the pivotal role of 
adipose tissue in metabolism, the processes that promote its development, expansion, 
and maintenance are poorly understood. Limitations in our understanding of adipose 
development are especially disconcerting due to the alarming increase in obesity in the 
U.S. and other developed nations. It is now estimated that two-thirds of Americans are 
overweight or obese, with similar levels reported in other developed nations (Centers 
for Disease Control and Prevention and Department of Human Services, Overweight 
and Obesity 2010, and National Institute of Diabetes and Digestive and Kidney 
Diseases, Prevalence statistics related to overweight and obesity 2010). 
 
1.1.2 Derivation of adipocytes from stem cells in vitro 
1.1.2.1 White adipocytes 
Numerous groups have tried to differentiate stem cells from various tissues into 
adipocytes. Below is a list of human tissue derived stem cells that could undergo 







Hair follicle derived mesenchymal stem cell  
(Bajpai, Mistriotis and 
Andreadis 2012) 
C-kit-positive cardiac stem cells (Kawaguchi 2011) 
Umbilical cord blood derived mesenchymal stem 
cells 
(Gong et al. 2012) 
Adipose derived stem cells (ADSCs) 
(Fink and Zachar 2011, 
Manini et al. 2011, Yu et al. 
2011) 
Bone marrow derived mesenchymal stem cells 
(BMSCs) 
(Fink and Zachar 2011, 
Manini et al. 2011, 
Janderova et al. 2003, Sekiya 
et al. 2002) 
Anterior cruciate ligament (ACL) stem cells (Zhang et al. 2011b) 
Medial collateral ligament (MCL) stem cells (Zhang et al. 2011b) 
Periodontal ligament (PDL) stem cells (Amin et al. 2011) 
Pancreatic stem cells 
(Seeberger, Eshpeter and 
Korbutt 2011) 
Dermal tissue stem cells (Manini et al. 2011) 
Dermal fibroblasts (Jaager and Neuman 2011) 
Synovial membrane (Arufe et al. 2010) 
Osteoarthritis derived synovial membrane cells 
(Hermida-Gomez et al. 
2011) 
Amniotic membrane (Diaz-Prado et al. 2010) 
Fetal muscle derived perivascular cells (Crisan et al. 2008) 
Bone marrow derived monocytes 
(Wang, Castro-Malaspina 
and Moore 1985) 
Trabecular bone cells 
(Nuttall et al. 1998, Noth et 
al. 2002) 
Skeletal muscle fiber progenitors (satellite cells) (Csete et al. 2001) 
 





differentiation in vitro 
 
 Mature white adipose tissue primarily consists of unilocular fat cells and stromal 
vascular fraction (SVF) that predominantly contains stem cells, preadipocytes and 
fibroblasts cells. While our group and others have primarily cultured SVF fraction of 
cells, others have also cultured unilocular fat cells in vitro using ‘ceiling culture’ method 
(Sugihara et al. 1986, Asada et al. 2011). The unilocular fat cells were collagenase 
digested from the fat tissue and cultured in a flask completely filled with medium, thus 
providing the fat cells with an air-free environment at 37° C.  Initially, the flasks are 
turned upside down, and the cells floated up in the medium and adhered to the top 
inner surface (ceiling surface) of the flasks. When the cells are firmly attached, the flasks 
are turned so that the cells are on the bottom inner surface and can be easily observed. 








Figure 1-4: Ceiling culture of mature fat tissue. Mature white fat tissue is chopped into 
small pieces and centrifuged. Sediments are not used in this culture. Floating tissue 
layer was incubated in culture flasks completely filled with medium. The mature fat 
cells floated to the top of the medium and adhered to the top ceiling surface of the flask. 
When the cells had attached firmly, the flasks was placed upside down to allow regular 
observation. Inset: histology of the floated tissue which consists for the most part of 
unilocular fat cells with a few stromal-vascular cells. Scale bar is 100 µm. Adopted from 
(Sugihara et al. 1986).  
 
  Different tissue-derived stem cells have different capacity to undergo 
adipogenic differentiation. For example, human ADSCs are found to be more 





years, different recipes exist to induce adipogenic differentiation of stem cells in vitro. 
Our group have induced adipocyte differentiation of human stem cells in vitro by 
exposition to a cocktail of adipogenic inducers containing insulin, glucocorticoids (such 
as Dexamethasone, Dex), agents that elevate cyclic adenosine Monophosphate (cAMP, 
such as the phosphodiesterase inhibitor, isobutylmethylxanthine (IBMX)), and 
Indomethacin (Stosich et al. 2007, Stosich and Mao 2007, Alhadlaq, Tang and Mao 2005). 
Adipogenic differentiation can also be induced by using Insulin, Dex, IBMX, and 
Triiodothyronine, T3 (Rodriguez et al. 2004, Laurent et al. 2008) or Insulin, Dex, IBMX, 
biotin, d-panthothenate, and rosiglitazone (or equivalent PPARγ2 ligand) (Yu et al. 
2011, Bunnell et al. 2008). All these treatments launch a transcriptional cascade that 
converges on the up-regulation of PPARγ expression, which functions as the master 
regulator of adipogenesis in vitro and in vivo (Monteiro et al. 2011).  
 
1.1.2.2 Transcription factors involved in adipogenesis 
Two families of factors are especially the lead players in the transcriptional control of 
adipocyte differentiation: CEBPs (CCAT/enhancer binding protein) and PPARγ 
(Peroxisome proliferator-activated receptor-γ) (Hu et al. 1996, Savopoulos et al. 2011). 
PPARγ is a member of the nuclear hormone receptor family that is expressed 
preferentially in adipose tissue (Tontonoz, Hu and Spiegelman 1995). It is expressed in 





process of adipogenesis (Tontonoz et al. 1994a). PPARγ heterodimerizes with another 
nuclear hormone receptor, retinoid X receptor (RXR) to bind to the DNA to be 
transcriptionally active (Rosen and Spiegelman 2000). PPARγ exists as two protein 
isoforms, PPARγ1 and PPARγ2 generated by alternative promoter usage and 
alternative splicing (Rosen and Spiegelman 2000). PPARγ1 is present at lower levels in 
adipose while PPARγ2 is the dominant isoform found in fat cells (Tontonoz et al. 1995). 
Studies have shown that the activation of PPARγ receptor promotes adipogenesis of 
bone marrow derived stromal cells. The C/EBPs belong to the basic-leucine zipper class 
of transcription factors. Different isoforms (C/EBPα, β, δ) have been described, all of 
which act as homo- and/or heterodimers formed via a highly conserved bZIP domain 
(Lekstrom-Himes and Xanthopoulos 1999). The C/EBPs tissue distribution is not 
restricted to fat cells. Induction of C/EBPβ and C/EBPδ leads to an increased expression 
of C/EBPα and PPARγ, and these two transcription factors then trigger the expression 
of genes important for lipid storage (Janderova et al. 2003).  But adipogenesis induced 
by C/EBPβ and C/EBPδ requires a PPARγ ligand (Wu, Bucher and Farmer 1996). 
Ectopic expression of C/EBPβ and δ stimulates adipogenesis in fibroblasts (Wu et al. 
1996, Yeh et al. 1995). This occurs through the C/EBP-mediated expression of PPARγ 
(Wu et al. 1996). Expression of large amounts of C/EBPα also promotes fat cell 
differentiation (Lin and Lane 1994). However, when expressed at more physiological 





of fibroblasts or myoblasts (Tontonoz et al. 1994a, Tontonoz et al. 1995). Therefore, 
cross-regulation between PPARγ and the C/EBPs may be crucial in initiating and 
maintaining the differentiated state of adipocytes (Spiegelman and Flier 1996).  
 
1.1.2.3 Molecular signature and localization of adipocyte precursors 
Adipose tissue can be harvested abundantly from a patient by means of a relatively 
noninvasive procedure. But the adipose tissue derived cells (ADSCs) comprise of a very 
heterogeneous population of cells (Li et al. 2011). Until now, efforts to characterize 
ADSCs have been limited to cultures established following plastic adherence 
(Zannettino et al. 2008). Therefore, understanding the functional characteristics of 
subpopulations will be useful in developing adipose stem cell-based therapies for 
regenerative medicine applications. Different strategies and various cell surface 
markers have been used to isolate subpopulations from adipose-derived stem cells. Li et 
al found that the cell population they isolated from SVF based on CD31-/CD34+ surface 
marker expression showed the most adipogenic potential (Li et al. 2011). Cultured 
expanded ADSCs established following STRO-1, CD146, or 3G5 cell surface marker 
selection appeared to possess the capacity to differentiate into functionally active 
adipocytes and be intimately associated with perivascular cells surrounding the blood 
vessels (Zannettino et al. 2008). In another study by another group, they identified 





(Rodeheffer, Birsoy and Friedman 2008).  They further tested these cells for their 
adipogenic potential in vitro and in vivo by transplanting them in lipoatrophic A-Zip 
mice (Rodeheffer et al. 2008). By using an alternative approach of lineage tracing in mice 
based on the expression of PPARγ in WAT, Tang and colleagues isolated cells that were 
able to undergo adipogenesis both in vitro and in vivo in nude mice (Tang et al. 2008). 
Upon further analyses, they found that these cells were CD45-/Ter119-/CD34+/Sca1+.  
Using a reporter gene under the control of the PPARγ promoter, they localized these 
cells along the blood vessel walls of WAT in adult mice, which are characterized by the 
expression of SMA, PDGFRβ and NG2. This observation therefore validates the long-
time observed close relationship between blood vessel formation and adipocyte 
development. 
 
1.1.2.4 Signaling Pathways involved in adipocyte differentiation 
The commitment of an undifferentiated cell to the adipogenic lineage requires a fine 
regulation of signaling pathways, transcription factors, and cofactors (Rosen 2005, 
Rosen and MacDougald 2006).  An understanding of the molecular regulation of 
adipogenic lineage should be of key interest in developing therapeutic strategies to 
control obesity and the related pathologies.  
 The mitogen-activated protein kinases (MAPKs) are a superfamily of 





(Chang and Karin 2001, Miloso et al. 2008) and are involved in many cellular processes 
such as proliferation, differentiation, and stress response (Zhang and Dong 2007). MEK1 
and MEK2 were the first of the ERK/MAP kinase subfamily to be cloned. The MEK1/2 
signaling pathway regulates cell proliferation and cell differentiation (Crews, 
Alessandrini and Erikson 1992, Alessi et al. 1994, Rosen et al. 1994). Inhibition of 
MEK1/2 pathway has been found to be important for the engagement of stem cells 
towards the adipogenic lineage (Donzelli et al. 2011, Janderova et al. 2003).  
 JAK/STAT signaling pathway transmits information from chemical signals 
outside the cell, through the cell membrane, and into gene promoters on the DNA in the 
cell nucleus, which causes DNA transcription and activity in the cell (Aaronson and 
Horvath 2002). It has been studied extensively in cytokine signaling during immune 
responses (Leonard and O'Shea 1998, Kisseleva et al. 2002, Levy and Darnell 2002). The 
Janus kinase (JAK) family comprises four members: JAK1, JAK2, JAK3, and Tyk2, 
whereas the STAT family has seven members: STAT1-4, STAT5A/B, and STAT6. It was 
found that signal transducer and activator of transcription 3 (STAT3) expression was 
markedly elevated in adipogenesis, whereas its up-regulation was unaffected when 
adipogenesis was inhibited by TNFα, suggesting that STAT3 expression might be not 
tightly regulated during adipogenesis (Stephens, Morrison and Pilch 1996). Later it was 
found that STAT3 is activated and bound to DNA during proliferative phases of 3T3-L1 





could inhibit adipogenic gene expression (Deng et al. 2006), suggesting that STAT3 
might function in 3T3-L1 adipocyte differentiation. This conclusion was confirmed by a 
recent study, in which STAT3 regulated adipocyte differentiation via PPARγ (Wang et 
al. 2009). Also, expression of STAT1, STAT5A and 5B is highly induced during 
adipogenesis and several reports indicate that STAT5 could be an important driver of 
adipogenesis (Stephens et al. 1996, Teglund et al. 1998, Nanbu-Wakao et al. 2002, Kawai 
et al. 2007). 
 Wnt signaling proteins activate various pathways in the cell that can be 
categorized into the canonical and noncanonical Wnt pathways (Nelson and Nusse 
2004). Through these signaling pathways, Wnt proteins play a variety of important roles 
in embryonic development, cell differentiation, and cell polarity generation (Logan and 
Nusse 2004). Wnt signaling proteins are secreted glycoproteins that signal through their 
Frizzled (Fz) receptors (Bhanot et al. 1996), and low density lipoprotein receptor-related 
protein (LRP) co-receptors (Bejsovec 2000) to have profound autocrine and paracrine 
effects on cellular differentiation and growth. Activity of Wnt signaling proteins is 
regulated by secreted inhibitors. For example, Wnt inhibitory factor-1 (Hsieh et al. 1999) 
and the family of secreted Frizzled-related proteins (sFRPs) (Uren et al. 2000) appear to 
bind and sequester Wnts from their receptors. Another family of Wnt inhibitors, 
dickkopf, binds to the Wnt co-receptor, LRP6, and inhibits interactions with the Wnt-Fz 





influenced not only by Wnt signaling proteins but also through regulation of Fz, LRPs, 
Wnt inhibitors, or downstream signaling intermediates. Wnt10b, a signaling protein 
secreted by one of Wnt gene family is found to be a potent inhibitor of adipogenesis in 
vitro (Bennett et al. 2002) and it blocks adipogenesis through activation of the canonical 
Wnt/β-catenin signaling pathway (Ross et al. 2000). 3T3-L1 preadipocytes when treated 
with soluble Wnt inhibitors, sFRP-1 and sFRP-2, stimulated spontaneous adipogenesis 
(Bennett et al. 2002). Wnt10b is considered to be an endogenous Wnt that maintains 
preadipocytes in an undifferentiated state and represses spontaneous adipogenesis. 
During adipogenesis, up-regulation of C/EBPβ significantly inhibits Wnt/β-catenin 
signaling primarily by reducing Wnt10b expression (Chung et al. 2012). 
 Notch signaling pathway plays a critical role in development and regeneration of 
stem cells as well as in determination of their fate (Artavanis-Tsakonas, Rand and Lake 
1999). Four paralogs of the Notch gene, Notch1, 2, 3 and 4, and five Notch ligands, 
including Jagged1, Jagged2, Delta1, Delta2 and Delta3, have been identified in 
vertebrates (Ohishi et al. 2000). In vertebrates, Notch signaling is mediated by 
intracellular interaction of Type I transmembrane ligands, such as Delta and Serrate 
with Notch receptors (Notch-1, -2, -3 and -4) (Huang et al. 2010). Once bound to its 
ligand, Notch receptor is cleaved by metalloprotease Tumor Necrosis Factor-α (TNFα) 
converting enzyme and the γ-secretase complex, at two sites, to generate the Notch 





CCAAT-binding protein (CBF-1). Notch activation through CBF1-NICD interactions can 
in turn activate transcription of various genes, such as Hes (Hairy⁄Enhancer of Split) 
(Wu and Griffin 2004, Grottkau et al. 2009), Hes-related repressor protein (HERP) (Iso et 
al. 2002, Iso, Kedes and Hamamori 2003), nuclear factor-κB (NF-κB) (Ohazama et al. 
2004) and PPAR (peroxisome-proliferator-activated receptor) (Nickoloff et al. 2002). 
Conflicting findings have been reported about the role of Notch signaling in adipocyte 
differentiation of preadipocytes. In one study, they claimed that Notch is dispensable in 
adipocyte specification. However, in another study Notch signaling inhibition 
promoted adipogenesis in mouse adipose stem cells (Huang et al. 2010) and human 
bone marrow derived mesenchymal stem cells (Vujovic et al. 2007).  
 Together these signaling pathways act as an adipogenic switch that needs to be 
turned on or off for adipogenic differentiation to proceed.  
 
1.1.3 Small molecules for adipogenesis 
Adipogenic differentiation is induced in part through small molecules in vitro. These 
include agents capable of elevating cAMP levels, such as forskolin or IBMX and agonist 
of the PPARγ2, such as rosiglitazone (BRL 49653) or troglitazone and the glucocorticoid 
receptor (GR), such as Dex (Halvorsen et al. 2001, Yu et al. 2011). 
 Numerous studies evaluating small pharmacological drugs that can further 





Huang et al showed that DAPT enhances adipogenesis of differentiated mASCs at an 
early stage (Huang et al. 2010). DAPT inhibits Notch-2-Hes-1 pathway and suppresses 
DLK-1⁄ Pref-1 and promotes PPARγ activation.  MEK1 and MEK2 activate p44 and p42 
through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, 
respectively. PD98059 and U0126 are specific inhibitors of the p42/44 mitogen-activated 
protein kinases (MAPK) pathway. PD98059 has been shown to inhibit MEK1, an 
enzyme that activates p42/44 MAPK (Alessi et al. 1995). While PD98059 stimulates 
adipogenesis and inhibits osteogenesis, U0126 does not have any effect on adipogenesis 
and decreases osteogenesis only slightly (Dang and Lowik 2004). Thiazolidinedione, 
such as pioglitazone, rosiglitazone, etc. down regulate Wnt/beta-catenin signaling 
(Wang et al. 2009) and promote adipogenesis in human bone marrow derived stem cells 
(Gimble et al. 1996). JAK pathway inhibitor 1 rescues adipocytes from Interferon γ 
(INFγ) induced dysfunction (McGillicuddy et al. 2009). Non-steroidal anti-
inflammatory drugs and phosphodiesterase inhibitors such as aspirin and caffeine are 
known to enhance adipogenesis of 3T3-L1 cells but have no significant effects on fat 
accumulation in human (Choi et al. 2003). 
 Thus, a morphology-based adipogenesis screening of a chemical library could 







1.1.4. Balance between Osteogenesis and Adipogenesis 
At a cellular level, both osteoblasts and adipocytes originate from bone marrow stem 
cells (BMSCs).  In majority of medical conditions associated with bone loss, including 
aging, there is an increased marrow adiposity possibly attributed to a balance shift 
between osteoblast and adipocyte differentiation of BMSCs. In ovariectomized or 
glucocorticoids-treated mammals, there is also an increase in bone marrow fat 
(Wronski, Walsh and Ignaszewski 1986, Kawai, Tamaki and Hirohata 1985, Martin and 
Zissimos 1991, Yao et al. 2008). This shift or increase in fat formation has been 
supported by two theories: a cross-talk between lineage-committed cell populations, 
adipocytes and osteoblasts or choice to support differentiation of one lineage over the 
other by multipotent MSCs.  
 A preference for one lineage differentiation has been documented by a number 
of in vitro experiments performed on multipotent BMSCs that demonstrated that factors 
inducing adipocyte differentiation (e.g. Leukemia inhibitor factor (LIF), 
dexamethasone) inhibit osteoblast differentiation (Beresford et al. 1992, Falconi, Oizumi 
and Aubin 2007), and likewise, osteoblast differentiation inducing factors (e.g. bone 
morphogenetic proteins, BMPs (Gimble et al. 1995), Wnt10b (Kang et al. 2007) inhibit 
adipogenesis. Several transcriptional factors, such as TAZ (transcriptional coactivator 
with PDZ-binding motif) (Hong et al. 2005), PPARγ2 (Akune et al. 2004), ΔFosB  





catenin and non-canonical Wnt signaling pathways (Taipaleenmaki et al. 2011) have 
been shown to have a control on the differentiation of BMSC into osteoblasts and 
adipocytes. Thus this shift is likely caused by activation or silencing of genes, signaling 
molecules and transcription factors. According to one study, BMSC derived adipocytes 
may regulate osteoblast differentiation in the aged bone through TGF-β-mediated 
canonical Wnt signaling (Zhang et al. 2011a). In another study, two secretory factors in 
the bone marrow microenvironment, secreted frizzled-related protein 1 (sFRP-1) and 
delta-like1 or preadipocyte factor 1 (Dlk1/Pref-1) have been shown to exert a regulatory 
effect on osteogenesis and adipogenesis (Abdallah and Kassem 2012). Expression of IL-1 
and TNFα in bone marrow may alter the fate of pluripotent BMSCs, directing cellular 
differentiation towards osteoblasts rather than adipocytes by suppressing PPARγ 
function through NF-kappaB activated by the TAK1/TAB1/NIK cascade (Suzawa et al. 
2003). Studies have shown that the activation of PPARγ receptor promotes adipogenesis 
and inhibits osteogenesis of BMSCs (Nuttall and Gimble 2004, Lecka-Czernik et al. 
2002). Especially PPARγ2 induces the differentiation process of adipose tissue 
associated with bone metabolism. Ligands of PPARγ not only activate this nuclear 
receptor but also suppress the Cbfa-1 (Core binding factor a1) (Nuttall and Gimble 2004, 
Akune et al. 2004, Lecka-Czernik et al. 2002, Jiang et al. 2008). To support the cross-talk 
theory, adipocyte secreted cytokines, such as adipsin, leptin, adiponectin, TNFα and 





microenvironment of bone marrow cells, including osteoblasts (Nuttall and Gimble 
2004, Perera et al. 2006).  
 Clinical and experimental observations have also revealed a reciprocal 
relationship between adipocyte differentiation and hematopoiesis in bone marrow 
(Snyder 1965). In the red bone marrow, where active hematopoiesis occurs, few 
adipocytes with lipid-laden droplets are observed (Sugimura and Li 2010). On the other 
hand, in yellow bone marrow where hematopoietic tissue is impaired during the aging 
process or abrogated by irradiation or chemotherapeutic drugs, more adipocytes with 
lipid-laden droplets are observed (Sugimura and Li 2010). Using bisphenol A diglycidyl 
ether that inhibits PPARγ activity and thus adipocyte differentiation, an increase in 








Figure 1-5: Mesenchymal stem cells in bone marrow (BM) give rise to osteoblastic cells 
and adipocytes. Under homeostasis, a balance in hematopoiesis is maintained by 
support from osteoblastic cells and suppression of adipocytes. But if the BM is exposed 
to stress or becomes aged, an imbalance in adipocytes suppresses hematopoiesis. 
Adopted from (Sugimura and Li 2010).  
 
  Thus, screening of small drug molecules that can directly target signaling 
molecules or pathways that promote one lineage differentiation over the other  can help 







1.2 PURPOSE OF STUDY 
1.2.1 Aim 1: To determine the effect of Pyrintegrin treatment in vitro 
Since the criteria for selecting stem cells from human adipose tissue depends on plastic 
adherence, human adipose derived stem cells not only contains stem cells, but also a 
heterogeneous population of other cells, such as preadipocytes, fibroblasts, 
macrophages, and endothelial cells.  Because there is no standard stem cell marker to 
distinguish cells that effectively differentiate into mature adipocytes in vitro, studies 
using such a heterogeneous cell population are very common. Although, upon treating 
this heterogeneous population with adipogenic differentiating medium, some of the 
cells accumulate lipids, which signifies formation of mature adipocytes, there involves a 
huge variation in the efficiency of differentiation potential of adipose derived stem cells.  
After treating these cells with adipogenic medium in vitro, we found only 40-50% of the 
cells had accumulated lipids after about 35 days of treatment (Stosich and Mao 2007).  
Pyrintegrin, a drug which was identified to promote pluripotent stem cell survival and 
self-renewal via high-throughput phenotypic chemical screening of 50,000 synthetic 
compounds (Xu et al. 2010), was further used to evaluate its potential for enhancing 
differentiation of mesenchymal stem cells.  
 To evaluate the effect of Pyrintegrin drug treatment on hADSCs culture, 





Aim 1: To test the effect of a novel drug, Pyrintegrin on differentiation potential of 
human adipose derived stem cells (hADSCs) 
1‐1: To evaluate the effect of Pyrintegrin on the differentiation potential of hADSCs 
treated with osteogenic, chondrogenic and adipogenic medium  
1‐2: To evaluate the effective dose of Pyrintegrin for up-regulating the expression of 
adipogenic markers in adipogenic medium treated hADSCs culture 
1‐3: To evaluate the effect of optimal dose of Pyrintegrin on the expression of 
adipogenic markers throughout the time period of differentiation of hADSCs 
1‐4: To test the effect of Pyrintegrin treatment on the lipid accumulation of adipogenic 
medium treated hADSCs culture 
1‐5: To test the effect of Pyrintegrin treatment alone on the expression of adipogenic 
markers of hADSCs culture 
1‐6: To evaluate the release profile of adipocytokines, leptin and adiponectin upon 
Pyrintegrin treatment of adipogenic medium treated hADSCs  
1‐7: To evaluate the release profile of triglycerides and glycerol upon Pyrintegrin 
treatment of adipogenic medium treated hADSCs  
 
1.2.2 Aim 2: To test the effect of the Pyrintegrin treatment in vivo 
In order to evaluate a therapeutic potential of the proposed adipogenic promoter, 





 To evaluate the effect of Pyrintegrin drug treatment in vivo, following aims were 
carried out: 
Aim 2: To determine if Pyrintegrin promotes adipose tissue formation in vivo  
2‐1: To test the hypothesis that Pyrintegrin treated cells can promote better adipose 
tissue formation than untreated cells in vivo  
2‐2: To test the hypothesis that local release of Pyrintegrin can promote adipose tissue 
formation in vivo  
 
1.2.3 Aim 3: To determine the signaling mechanism of Pyrintegrin  
As described in Section 1.1.2.4, we wanted to evaluate the signaling mechanism of 
Pyrintegrin responsible for promoting adipogenic differentiation in hADSCs.  
 To evaluate the signaling mechanism targeted by Pyrintegrin drug treatment, 
following aims were carried out: 
Aim 3: To evaluate the signaling pathway targeted by Pyrintegrin in human adipose 
derived stem cells (hADSCs) 
3‐1: To test whether Pyrintegrin is a PPARγ agonist   
3‐2: To evaluate the signaling pathway targeted by Pyrintegrin  
3-3: To evaluate the role of Pyrintegrin in inhibiting BMP pathway 
3‐4: To evaluate the effect of Pyrintegrin drug treatment on the expression of osteogenic 





3‐5: To evaluate the effect of Pyrintegrin drug treatment on calcium deposition of 




















1.3 SIGNIFICANCE AND ORGANIZATION 
Until now, traditional methods for identifying small molecule inhibitors that can solely 
promote differentiation of stem cells have not been well studied.  This thesis study will 
try to explore the potential role of a small molecule drug, initially identified to up-
regulate embryonic stem cells survival and proliferation, on differentiation potential of 
mesenchymal stem cells.  
 
Figure 1-6: Chemical structure of Pyrintegrin (Ptn). Adopted from (Xu et al. 2010). 
 
 Pyrintegrin induced adipogenesis includes a validation of a reproducible protocol to 
derive adipogenic‐like cells from hADSCs with a single induction factor (Chapter 2). 
Human ADSCs have been considered as an important cell source for soft tissue 
engineering because of its accessibility, high proliferation capacity, and multipotent 
differentiation capability (Gimble and Nuttall 2011). However, biochemical factors that 
can accelerate adipogenic differentiation of hADSCs without compromising its function 





adipogenic differentiation, which may provide a simple and efficient tool for 
MSC‐based soft tissue engineering, especially for breast and facial reconstruction, etc. In 
addition, we investigate therapeutic potentials of Pyrintegrin‐induced adipogenesis 
both in vitro (Chapter 2) and in vivo (Chapter 3) for soft tissue reconstruction. As 
described in Section 1.1.3, the current tenet in treating soft tissue abnormalities is 
injecting autologous fat tissue, which has potential risks such as hematoma or cysts 
formation, infection and other serious complications.   
 This thesis research for the first time to our knowledge, examines the role of a 
novel drug, Pyrintegrin in regulating differentiation of mesenchymal stem cells. The in 
vitro study included exogenous treatment of hADSCs with Pyrintegrin, and evaluating 
its effect which may provide important clues. In addition, delivery of Pyrintegrin in vivo 
model may represent a minimally invasive approach for regenerating soft tissue defects 
involving fat formation, vascularization etc. Finally, Pyrintegrin‐induced adipogenesis 
potentially has significant bioengineering and therapeutic potentials. This drug with 
strong proadipogenic effects can be applied to regulate adipogenic differentiation of 







Figure 1-7: Common types of plastic and reconstructive surgery. Treat disfiguring 
Facial wrinkles and sagging due to aging or vanity (A), Mastectomy or Lumpectomy (B) 
and injuries and conditions (C).  
 
Single factor induced adipogenesis may initiate additional efforts to understand fat 
formation related disorders, including yellow bone marrow, by targeting the 
Pyrintegrin‐involved adipogenic pathways. Upon confirmation of its proadipogenic 
















CHAPTER 2. PYRINTEGRIN PROMOTES STEM CELL 
ADIPOGENIC DIFFERENTIATION 
2.1 INTRODUCTION 
There is growing evidence from both in vitro and in vivo studies that stem cells derived 
from adipose tissue (ASCs) isolated from humans and other species do demonstrate 
multi-potential differentiation capability. These multi-lineage capacity include the 
adipocyte (Zuk et al. 2002, Halvorsen et al. 2001, Sen et al. 2001, Zuk et al. 2001), 
chondrocyte (Wickham et al. 2003, Erickson et al. 2002, Zuk et al. 2002, Zuk et al. 2001), 
hematopoietic supporting (Kilroy et al. 2007, Corre et al. 2006), hepatocyte (Seo et al. 
2005, Talens-Visconti et al. 2007, Talens-Visconti et al. 2006),  neuronal-like (Zuk et al. 
2002, Safford and Rice 2005, Safford et al. 2002, Safford et al. 2004, Kang et al. 2004, 
Krampera et al. 2007), osteoblast, pancreatic (Timper et al. 2006), and skeletal myocyte 
(Zuk et al. 2002, Zuk et al. 2001, Lee and Kemp 2006, Mizuno et al. 2002). 
 The first stage in the differentiation of stem cells for most cell lineages is growth 
arrest. Initial growth arrest is achieved in vitro after cell-cell contact inhibition. For 
adipogenic differentiation in vitro, the differentiation cocktail regimen is started only 
after the initial growth arrest and is then followed by one or two additional rounds of 
cell division known as clonal expansion. The differentiation cocktail consists of Insulin, 





methylisobutylxanthine (IBMX; a phosphodiesterase inhibitor), and Dexamethasone 
(Dex, a glucocorticoid hormone). The effect of insulin on differentiation has been shown 
to occur through cross-activation of the IGF-1 receptor (Niemela et al. 2007). 
Indomethacin promotes adipogenesis through a cyclooxygenase independent 
mechanism (Styner et al. 2010). IBMX primarily acts by up-regulating cAMP levels. Dex 
is believed to operate through activation of the glucocorticoid receptor (GR), which is a 
nuclear hormone receptor in the same large superfamily as peroxisome proliferator 
activated receptor (PPAR). The combination of cAMP with insulin and Dex 
reproducibly produced the most robust effects, and this is still the preferred regimen for 
inducing fat cell formation in vitro. After clonal expansion, the preadipocytes enter a 
second and final period of growth arrest, which is followed by differentiation into the 
mature adipose fat cell phenotype. 
 Transcription factors play an important role in adipocyte differentiation (Nayan 
2003). The expression of the transcription factors peroxisome proliferator activated 
receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα) marks the 
permanent period of growth arrest followed by expression of the fully differentiated 
phenotype. Forced expression of PPARγ in 3T3-L1 preadipocytes using retroviral 
vectors leads to adipogenesis in the absence of standard differentiating medium or any 
exogenous PPARγ ligand (Li and Lazar 2002). The use of synthetic ligands for PPARγ 





Hence, PPARγ and C/EBPα mRNA and protein expression levels are critical in 
understanding the adipogenic differentiation potential and stage of stem cells. Their up-
regulation is then followed by expression of most or all of the genes that characterize 
mature adipocyte phenotype and release of adipocytokines along with massive 
triglyceride accumulation.  
 Adipocytokine or adipokine is a term that is used for a bioactive product 
secreted by white adipose tissue. The adipose tissue secretes a wide variety of 
adipocytokines, such as Adiponectin, Leptin, Resistin, Visfatin, Apelin etc (Conde et al. 
2011). Adipocytokines are pleiotropic secretory molecules that exert their effect through 
autocrine, paracrine, endocrine, or juxtacrine cross talk signals in a wide variety of 
physiological or pathophysiological instances (Hermida-Gomez et al. 2011). It has now 
become increasingly clear that adipocytokines are pivotal in the context of obesity-
related problems, diabetes and the biochemical shifts that lead to metabolic syndrome 
and inflammatory and/or autoimmune conditions. Leptin is a product of obese (Ob) 
gene and it is manufactured primarily by the adipocytes of the white adipose tissue, 
and its level in the serum is directly proportional to the total amount of body fat. Mice 
with mutations in the Ob gene that block the synthesis of leptin are obese and diabetic, 
and have reduced activity, metabolism, and body temperature. When these mice were 
treated with injections of leptin, they lost their excess fat and returned to normal body 





Acrp30) has wide ranging paracrine and endocrine effects on metabolism and 
inflammation. It promotes adipocyte differentiation, fatty acid catabolism, and insulin 
sensitivity and is negatively correlated with obesity, type 2 diabetes, and atherogenesis 
(Lara-Castro et al. 2007). 
 Adipose tissue is also responsible for producing a major percentage of total 
quantity of fat synthesized by our body (Shapiro and Wertheimer 1948). Chemically, 
fats are triglycerides, triesters of glycerol and any of several fatty acids. Fatty acids are 
usually derived from triglycerides or phospholipids. Fatty acids are an important 















2.2 MATERIALS AND METHODS  
2.2.1 Human adipose derived stem cell isolation and expansion 
Human adipose derived stem cells (hADSCs) were obtained as a generous gift from Dr. 
Farshid Guilak’s lab, Duke University Medical Center, North Carolina, USA. Human 
ADSCs were isolated from liposuction waste of subcutaneous adipose tissue as 
described previously (Bunnell et al. 2008). The lipoaspirate is thoroughly washed 
several times with the same volume of Dulbecco's PBS (D-PBS; without calcium 
chloride and magnesium chloride; Gibco, Invitrogen Corporation, Carlsbad, CA) as the 
aspirate to remove the blood layer completely. After this, the aspirate is incubated with 
warm D-PBS containing 1% Bovine serum Albumin (BSA; Sigma-Aldrich, St. Louis, 
MO), 0.1% wt./vol. of Type I collagenase solution (Worthington Biochemical Products, 
Lakewood, NJ) and 2 mM Calcium Chloride (CaCl2; Sigma-Aldrich, St. Louis, MO) in a 
37 °C water bath shaker and the solution is gently shaken for 1 h to ensure that 
individual cells are released from the strands of fibrous tissue.  The aspirate is then 
centrifuged at 300g at 21°C for 5 min. After centrifugation, the floating mature 
adipocyte layer and the aqueous D-PBS–collagenase supernatants are aspirated, leaving 
behind 5 ml of D-PBS on each pellet of cells. The cell pellet is then resuspended in 10 ml 
of growth medium and centrifuged at 300g at 21 °C for 5 min. The growth medium is 
defined as Dulbecco’s modified Eagle’s medium:Nutrient mixture F12 





(Antibiotic–Antimycotic 100X contains 10000 units of Penicillin, 10000 µg of 
Streptomycin and 25 μg of amphotericin B; Gibco, Invitrogen Corporation, Carlsbad, 
CA) and 10% Fetal Bovine Serum (FBS; Life Technologies, Grand Island, NY). The 
supernatant is removed and the cell pellet is again washed in growth medium for two 
more times. After the final washing step, the cells are resuspended in a total of 105 ml 
stromal medium per 100 ml of lipoaspirate digest. 10 ml of cell suspension is plated per 
100 mm petri dish (Corning Incorporated, Corning, NY). Cells are allowed to attach to 
the petri dish for a minimum of 5 days in 5% CO2 at 37°C without any medium change. 
After 5 days, the medium is changed twice per week until the cells become confluent. 
At 80‐90% confluence, cells are trypsinized, washed, centrifuged, resuspended in 
growth media as passage 1 (P1) and plated at a plating ratio of 1:4 or frozen in a 
freezing solution (80% (vol/vol) FBS, 10% (vol/vol) DMEM/Ham's F-12 and 10% 
(vol/vol) Dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO)) and stored in 
liquid nitrogen, as per our previous protocol (Alhadlaq et al. 2004, Marion and Mao 
2006, Clark et al. 2005). The cells are counted using Trypan blue stain 0.4% and 
Countess Automated cell counter (Invitrogen Corporation, Carlsbad, CA). All the 
cultures are maintained in 5% direct heat Autoflow CO2 air-jacketed incubators (Nuaire, 







2.2.2 Treatment with Pyrintegrin 
As a pilot study, an effective dose of Pyrintegrin (Stemgent, Cambridge, MA) to induce 
adipogenic differentiation of hADSCs was determined. P5 hADSCs were 
culture‐expanded in monolayer at a density of 5 × 104 cells/cm2 in 24‐well culture plates. 
At 80 ‐ 90% confluence, hADSCs were treated with control medium (Control), 
adipogenic differentiation medium (ADM) and ADM supplemented with 0, 2, 5 and 10 
µM of Pyrintegrin.  For assessing the role of Pyrintegrin treatment alone on hADSCs, P5 
hADSCs were treated with control medium supplemented with 0, 2, and 10 µM of 
Pyrintegrin and ADM.  
 
2.2.3 Multi-lineage differentiation potential of Pyrintegrin treated cells 
Human ADSCs at culture passage P4–P7 were used for the differentiation study. 
Human ADSCs were seeded at a density of 5 × 104 cells/cm2 on tissue culture dishes. For 
differentiation experiment, the cells are allowed to become confluent as per our 
previously well-established protocols (Alhadlaq et al. 2005, Moioli et al. 2010, Stosich 
and Mao 2007, Alhadlaq et al. 2004, Alhadlaq and Mao 2005, Lee et al. 2010, Moioli and 
Mao 2006). For adipogenic differentiation, the cells were treated with adipogenic 
differentiation medium (ADM) composed of growth medium supplemented with 
adipogenic supplements such as 1 µM Dexamethasone (Dex), 10 µg/ml insulin, 0.5 µM 





MO). Human ADSCs treated with growth medium without adipogenic supplements 
represented control cultures. Human ADSCs treated with adipogenic medium 
represented ADM cultures. Human ADSCs treated with adipogenic medium containing 
Pyrintegrin represented ADM+Ptn cultures.  For osteogenic differentiation, the cells 
were treated with osteogenic differentiation medium (ODM) composed of growth 
medium supplemented with osteogenic supplements such as 100 nM Dexamethasone 
(Dex), 0.05 mM L-ascorbic acid-2-phosphate, and 10 mM β-glycerophosphate disodium 
salt hydrate (Sigma-Aldrich, St. Louis, MO). Human ADSCs treated with osteogenic 
medium represented ODM cultures. Human ADSCs treated with osteogenic medium 
containing Pyrintegrin represented ODM+Ptn cultures. For chondrogenic 
differentiation, the cells were treated with chondrogenic differentiation medium (CDM) 
composed of growth medium made with high glucose DMEM:F12+Glutamax medium 
containing 1% antibiotics, 1% FBS, 1% ITS+1, 100 nM of Dexamethasone, 50 µg/mL of L-
ascorbic acid-2-phosphate,  40 µg/mL of L-Proline, 100 µg/mL of Sodium Pyruvate 
(Sigma-Aldrich, St. Louis, MO), and 10 ng/mL of TGFβ3 (R&D Systems Inc., 
Minneapolis, MN). During the course of the differentiation experiment, the medium 
was changed twice a week. Experiments for the assessment of differentiation were 






2.2.4 Real Time‐Polymerase Chain Reaction (RT-PCR) analysis 
 For RT-PCR, passage P5 hADSCs were seeded at a density of 5 × 104 cells/cm2 on 
a 24 well tissue culture plate (Corning Incorporated, Corning, NY). The total RNA was 
isolated using PureLink RNA Mini kit (Life Technologies, Grand Island, NY) as per 
manufacturer’s instructions. RNA samples were eluted in 30 μl of DEPC‐water. Total 
RNA was quantified using NanoDrop 1000 Spectrophotometer (Invitrogen, Carlsbad, 
CA) and stored at ‐80 °C prior to reverse transcription.  
 All RNA samples were reverse transcribed using a High‐Capacity cDNA Reverse 
Transcription kit and Veriti 96-well thermal cycler (Applied Biosystems, Foster City, 
CA). The cDNA was synthesized using 0.1-0.2 µg of RNA to obtain 20 µL of cDNA. As 
per manufacturer’s protocol, appropriate amounts of buffer, 100 mM dNTPs, random 
primers, reverse transcriptase, RNase inhibitor, and nuclease‐free water were added to 
the RNA samples. The RNA was then converted into cDNA using the thermal cycling 
parameters which were 25 °C for 10 min; 50 °C for 50 min; 85 °C for 5 min; followed by 
cooling to 4°C. All cDNA samples were stored at ‐20 °C until further use. For the PCR 
reaction, the cDNA samples were mixed with appropriate amounts of TaqMan
® 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA), primers, and 
nuclease‐free water as per manufacturer’s protocol. The DNA was amplified using PCR 
cycle parameters which were 50°C for 2 min; 90°C for 10 min; 40 cycles of 95°C for 15 s 





Peroxisome proliferator-activated receptor γ (PPARγ, Hs01115513_m1), and CCAT-
enhanced binding protein α (C/EBPα, Hs00269972_s1) gene-specific FAM dye tagged 
primers were used. All the primers were purchased from Applied Biosystems, 
Carlsbad, CA. The analysis of gene expression was carried out using ViiA™7 Real-Time 
PCR System (Applied Biosystems, Carlsbad, CA) in 25 µl reaction volume. The 
endogenous house-keeping Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
Hs02758991_g1) gene-specific FAM dye tagged primer was used to normalize gene 
expression and relative quantification was performed using Comparative ΔΔCt method 
and Standard reagents. 
 
2.2.5 Lipid staining of adipogenic differentiated cells 
 After removing the culture medium from the wells, human ADSC cultures were 
washed with Phosphate Buffer saline (PBS, Sigma-Aldrich, St. Louis, MO), fixed in 
warmed 4% paraformaldehyde solution (Fisher Scientific, Pittsburgh, PA) for 10-30 min 
at room temperature. After removing the fixative, the cells were gently washed twice 
with PBS and then stained with LipidTOXTM neutral lipid stain (Invitrogen, Carlsbad, 
CA) for 10-15 mins as per manufacturer’s protocol. The plates were imaged using an 
inverted microscope (Leica, Northvale, NJ) and a Rhodamine filter (Chroma, 
Rockingham, VT). Brightfield and fluorescent images were captured using a microscope 





2.2.6 Biochemical assays for adipogenic markers 
Human ADSCs were plated at a density of 5x 104/cm2 in a 24 well plate. To determine 
the total amount of cytokines secreted by the individual groups, the culture medium 
and lysed cell supernatant were individually collected at 2 and 4 week time point. The 
culture medium was first collected from various groups on day 14 and 28 and stored at 
-80° C for further use. Then the cells were lysed using 1% Triton-X solution (Sigma-
Aldrich, St. Louis, MO) and the cell culture supernatant was collected by scrapping the 
cells with a sterile cell scraper (Fisher Scientific, Pittsburgh, PA). The supernatant was 
briefly sonicated for 10 s using an ultrasonic water bath (Fisher Scientific, Pittsburgh, 
PA) while the samples are kept on ice and stored in -80° C till further use. The total 
amount of secreted human adiponectin and leptin were measured using an enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN) as per 
manufacturer’s protocol. The absorbance was read using a microplate reader (Biorad 
Labs, Hercules, CA).  
 DNA content was measured using Quant-iT™ PicoGreen® dsDNA Assay Kit 
(Life Technologies, Grand Island, NY) as per manufacturer’s protocol. A high-range 
standard curve of 1 µg/mL was used for measuring the DNA concentration of the 
samples. The samples were prepared in a 96 well black bottom plate (Fisher Scientific, 





standard fluorescein wavelengths (excitation ~480 nm, emission ~520 nm, Molecular 
Devices, Sunnyvale, CA).  
 Total Triglycerides and Glycerol content of the samples were detected by 
processing the sample lysate with Free Glycerol Determination kit (Sigma-Aldrich, St. 
Louis, MO) as per manufacturer’s protocol and the absorbance was read with a 
microplate reader at 540 nm.  
 
2.2.7 Statistical analysis  
Upon confirmation of normal distribution, all quantitative data were analyzed 
using a one‐way analysis of variance (ANOVA) with post‐hoc Bonferroni tests to 
determine significant differences between or within groups, using a statistical 
package (SPSS, Chicago, IL). Results were considered significant if a value of p < 0.05 



















2.3.1 Regulation of adipogenic specific markers  
Passage 6-7 hADSCs isolated from the subcutaneous abdominal human fat tissue were 
plated at a density of 5 X 103 cells per cm2. The cells are culture expanded in a 24 well 
tissue culture plate. At 80-90% confluency, hADSCs were induced to differentiate for 3 
days in Control medium (Control), osteogenic differentiation medium (ODM), ODM 
containing 2 µM of Pyrintegrin (ODM+Ptn), chondrogenic medium (CDM), CDM 
containing 2 µM of Pyrintegrin (CDM+Ptn), adipogenic differentiation medium (ADM) 
and ADM containing 2 µM of Pyrintegrin (CDM+Ptn). The addition of Pyrintegrin at 2 
µM concentration to any of the differentiation medium significantly increased the 
expression of adipogenic specific gene, PPARγ as compared to hADSCs treated with 








Figure 2-1: Regulation of stem cell differentiation specific markers. Relative gene 
expression of mRNA markers for adipogenesis was quantified after 4 days in hADSCs 
culture treated with Control, ODM, ODM+Ptn, CDM, CDM+Ptn, ADM and ADM 
containing Pyrintegrin. The addition of Ptn at 2 µM concentration to any of the 
differentiation medium significantly increased the expression of adipogenic specific 









2.3.2 Optimal dose of Pyrintegrin to induce adipogenic differentiation 
At 80-90% confluency, hADSCs were induced to differentiate for 4 days in control 
medium (Control), adipogenic differentiation medium (ADM), ADM containing 2, 5 or 
10 µM of Pyrintegrin (ADM+Ptn). The addition of Pyrintegrin at 2 µM concentration to 
the differentiation medium significantly increased the expression of both the adipogenic 
specific genes, PPARγ and C/EBPα as compared to hADSCs differentiated in ADM 
alone as shown in Figure 2-2. At 5 µM concentration, Pyrintegrin drug was effective in 
up-regulating only PPARγ but not C/EBPα expression and at 10 μM concentration, 
Pyrintegrin drug was not effective in up-regulating both PPARγ and C/EBPα 
expression as compared to 2 µM treated Pyrintegrin group. Hence, 2 µM of Pyrintegrin 







Figure 2-2: Optimal dose of Pyrintegrin for inducing adipogenic differentiation in 
adipogenic medium treated hADSCs. Relative gene expression of mRNA markers for 
adipogenesis was quantified in hADSCs culture treated with Control, ADM and ADM 
containing varying doses of Pyrintegrin. By 4 days, PPARγ and C/EBPα mRNA 
expressions were significantly increased only in 2 µM Pyrintegrin treatment group in 
comparison with control and ADM treated group. At 5 and 10 µM concentration, 
Pyrintegrin drug was not effective in up-regulating both PPARγ and C/EBPα 







2.3.3 Time course analysis of adipogenic markers 
Figure 2-3a, b show changes in PPARγ and C/EBPα gene pattern expression, 
respectively throughout the time lapse differentiation of hADSCs treated with control 
medium (Control), adipogenic differentiation medium (ADM), or ADM containing 2 
µM of Pyrintegrin (ADM+Ptn).  The ADM+Ptn treated group showed substantial 
amount of up-regulation of both the genes throughout the differentiation time point. 
We saw a substantial drop in PPARγ expression on Day 7 in ADM treated group. This 
effect was also seen in ADM+Ptn group but was delayed by a week. Pyrintegrin 
maintained higher PPARγ expression for entire differentiation time point than any 
group. Also, Pyrintegrin maintained a continuous substantial increase in C/EBPα 











Figure 2‐3: Time course analysis of adipogenic markers. Relative gene expression of 
mRNA markers for adipogenesis was quantified in hADSCs culture treated with 
Control, ADM and ADM containing 2 µM of Pyrintegrin. Over the period of 28 days, 
Pyrintegrin treatment maintained a higher up regulation of both PPARγ (a) and 









2.3.4 Lipid staining of differentiated cells  
To assess the degree of differentiation, lipid droplets were stained with a fluorescent 
lipid dye. Upon 4 weeks of induction with ADM or ADM+Ptn, we found that addition 
of 2 µM of Pyrintegrin to the ADM markedly increased the number of visible lipid 
droplets compared to hADSCs differentiated in ADM as evidenced by more lipid 
staining as shown in Figure 2-4.  
 
 
Figure 2‐4: Human adipose derived stem cells (hADSCs) undergo lipid accumulation 





differentiation in hADSCs culture treated with ADM (A and A1) and ADM+Ptn (B and 
B1) treated medium for 4 wks.  Using a fluorescent lipid staining dye, we found that 
addition of 2 µM of Ptn to the ADM markedly increased the number of visible lipid 
droplets compared to hADSCs differentiated in ADM as evidenced by more lipid 


















2.3.5 Directing stem cell fate 
At 80-90% confluency, hADSCs were induced to differentiate for 4 days either in control 
medium (Control), control medium containing 2 (Control+Ptn2) or 10 µM of Pyrintegrin 
(Control+Ptn10), and adipogenic differentiation medium (ADM). As shown in Figure 2-
5, the addition of Pyrintegrin to the control medium at both the concentrations 
significantly up-regulated the adipogenic specific gene, PPARγ as compared to hADSCs 
treated with control medium. But only Pyrintegrin at 10 µM concentration was able to 
show a similar expression of PPARγ as ADM treated group.  Both 2 and 10 μM 
concentration of Pyrintegrin failed to increase the expression of C/EBPα as compared to 
hADSCs differentiated in ADM group, but was potent enough to up-regulate C/EBPα 
expression compared to control medium treated group.   This shows that Pyrintegrin 






Figure 2‐5: Optimal dose of Pyrintegrin for inducing adipogenic differentiation in 
hADSCs. Relative gene expression of mRNA markers for adipogenesis was quantified 
in hADSCs culture treated with Control, Control containing varying doses of 
Pyrintegrin and ADM medium. By 4 days, PPARγ mRNA expression was significantly 
increased in both 2 and 10 µM Pyrintegrin treatment group in comparison with control 
group. But C/EBPα mRNA expression did not increase in any of the Pyrintegrin 









2.3.6 Secretion of adipocytokines 
To assess the effect of the Pyrintegrin drug on the differentiation of hADSCs, at 80-90% 
confluency, the cells were differentiated in the control, ADM and ADM+Ptn medium 
for up to 4 weeks. Figure 2-6a, b show the effect of various groups on adiponectin and 
leptin secretion respectively normalized over DNA content during differentiation over 
the 4 week time period. As compared to ADM group, addition of 2 µM concentration of 
Pyrintegrin to the ADM significantly increased the expression of adipogenic specific 
cytokines, adiponectin as well as leptin after 2 and 4 weeks. There was no significant 
difference between the ADM group cytokine levels at 4 weeks and ADM+Ptn group 
cytokine levels at 2 weeks. This further confirms that Pyrintegrin not only accelerates 
stem cell adipogenic differentiation but also increases the functional characteristics of 









Figure 2‐6: Secretion of Adipocytokines. Absolute release profile of adipocytokines was 
quantified in hADSCs culture treated with Control, ADM and ADM containing 2 µM of 
Pyrintegrin. At both 2 and 4 weeks, Pyrintegrin treatment maintained a higher release 
profile of both Adiponectin (a) and Leptin (b) cytokines as compared to control and 









2.3.7 Secretion of total triglycerides and glycerol 
To determine the amount of total triglycerides and glycerol released by hADSCs during 
induction, the cells were differentiated in the control, ADM and ADM+Ptn group for up 
to 4 weeks, and the cell lysate and culture medium were collected individually at 2 and 
4 week time point. Figure 2-7a shows the total triglyceride content normalized over 
DNA content for the various groups. At both 2 and 4 weeks, Pyrintegrin drug treatment 
showed substantial release of triglyceride compared to the other groups. The total 
content of triglycerides was determined by enzymatic hydrolysis of triglycerides to 
glycerol and free fatty acids accompanied by enzymatic measurement of glycerol 
released (Bucolo and David 1973). Figure 2-7b shows the glycerol content normalized 
over DNA content for the various groups. At both 2 and 4 weeks’ time point, 
Pyrintegrin drug treatment showed substantial release of endogenous glycerol 
compared to the other groups. The glycerol content of Pyrintegrin treated group at 2 
weeks was much higher than ADM treated group at 4 weeks. This shows that 









Figure 2‐7: Secretion of fatty acids. Absolute release profile of glycerol and total 
triglycerides was quantified in hADSCs culture treated with Control, ADM and ADM 
containing 2 µM of Pyrintegrin. At both 2 and 4 weeks, Pyrintegrin treatment 
maintained a higher release profile of both Glycerol (a) and Total triglycerides (b) as 









The present data shows that Pyrintegrin enhances adipogenesis of human ADSCs in the 
presence of adipogenic differentiation medium in 2-D cell culture over the period of 28 
days. At the molecular level, adipogenic differentiation enhancement by Pyrintegrin 
was monitored by measuring the adipogenic gene expression of PPARγ and C/EBPα 
(Figure 2-2) and also by measuring the level of adipocytokines such as adiponectin and 
leptin over the course of 4 weeks (Figure 2-6).  
 PPARγ has been shown to act as a key transcription factor in adipogenesis in 
vitro and in vivo. PPARγ activators such as prostaglandin derivatives and anti-
inflammatory drugs such as indomethacin and the synthetic insulin-sensitizing 
thiazolidinedione are known as strong inducers of adipogenesis (Rosen and Spiegelman 
2000).  Although these chemicals are potent in up-regulating one of the most important 
transcription factors involved in adipogenesis, the requirement for insulin, 
dexamethasone, and cAMP in vitro still remains to promote full fledge adipogenesis 
(Grimaldi 2001). This is similar to what we observed with the use of Pyrintegrin. While 
Pyrintegrin treatment alone significantly up-regulated adipogenic markers in hADSCs, 
by itself Pyrintegrin fell short of inducing an up-regulation as powerful as ADM 
medium treated group. Only in the presence of adipogenic inducers, Pyrintegrin was 





 Leptin regulates body fat mass by inducing an afferent signal relayed by our 
brain to adipocytes via a feedback mechanism (Halaas et al. 1995, Maffei et al. 1995, 
Coleman 1978). Therefore, obese (ob) mice that lack ob gene that encodes for hormone 
leptin are massively obese and when normal and ob-deficient mice are injected with 
synthetic leptin, they lose weight (Maffei et al. 1995). On the other hand, PPARγ 
activation inhibits leptin gene transcription in 3T3-L1 cells, and human studies show a 
reduction in circulating leptin with thiazolidinedione treatment (Shimizu et al. 1998, 
Kallen and Lazar 1996). However, Pyrintegrin treatment significantly increased the 
release of leptin as shown in Figure 2-6.  
 Taken together, the present findings provide evidence of a reproducible protocol, 
which is based on a single factor Pyrintegrin, to induce differentiation of hADSCs into 
adipogenic‐like cells in vitro. The current studies for the first time demonstrate that 
Pyrintegrin drug treatment can accelerate adipocyte differentiation and augment lipid 
accumulation, adiponectin and fatty acid secretion in adipogenic medium differentiated 










CHAPTER 3. PYRINTEGRIN PROMOTES FAT 
FORMATION IN VIVO 
3.1 INTRODUCTION 
Tissue engineered adipose tissue could be used in plastic and reconstructive surgery to 
augment soft tissue lost due to mastectomy, lumpectomy or facial trauma. The three-
dimensional space provided by a scaffold should permeate neovascularization as well 
tissue ingrowth to promote engineered adipose tissue formation. This scaffold 
utilization method will also have utility in the isolation and preparation of adipocytes 
for implantation into a patient for the purpose of tissue augmentation following trauma 
or cosmetic surgery. For our study, we designed our scaffold using Polycaprolactone, 
PCL, as it has been extensively studied as a biodegradable material for various tissue 
engineering applications. The objective of this study is two-fold; one is to determine 
whether better adipose tissue can be engineered by adsorbing drug, Pyrintegrin to the 
scaffold compared to Pyrintegrin-free scaffold and second is to determine whether 
better adipose tissue can be engineered using a scaffold with cells treated with drug, 
Pyrintegrin than untreated cells.  
 To our knowledge, the first objective to promote adipogenesis within a scaffold 
in vivo using a chemical drug has never been approached. On the other hand, the use of 





adipogenesis in vitro as well as in vivo (Cho et al. 2006, Kawaguchi et al. 1998, Masuda, 
Furue and Matsuda 2004).  While a low dose (1 µg) controlled release of bFGF was the 
most effective concentration in promoting adipogenesis 6 weeks after implantation into 
nude mice, a high dose (10 µg) of bFGF produced a more inflammatory response 
(Kimura et al. 2003). De novo adipogenesis can occur without implanting adipose 
derived stem cells (Hiraoka et al. 2006, Kawaguchi et al. 1998, Masuda et al. 2004, 
Yuksel et al. 2000) because preadipocytes from surrounding adipose tissue can be 
recruited into the scaffold, which then differentiate into mature adipocytes. But in 
patients diagnosed with breast cancer, continuous radiation therapy destroys the 
surrounding left over adipose tissue; thereby leaving very few cells to fill up the void 
space. Under such circumstances, adipose tissue engineering techniques would require 
exogenous progenitor cells, which upon implantation are expected to differentiate into 
mature adipocytes.  
Hence, we decided to test our second objective since clinically, it might be 
possible that the implantation of ADSCs including preadipocytes might be a 
prerequisite for a successful outcome of adipose tissue engineering. In one study, 106 
preadipocytes cultured in the medium supplemented with epidermal growth factor 
(EGF) were seeded onto collagen sponges and then implanted into mice. They found 
that implantation of preadipocytes was necessary for the promotion of adipogenesis 





fibrin gel into nude mice, a better adipose tissue was regenerated (Torio-Padron et al. 
2007).  One study evaluated the optimal cell number to be injected in vivo for a better 
tissue outcome. They found that from the tested 2X106 and 8 X106 cells density, 2X106 
was the optimal cell dose that generated maximum adipose tissue (Tsuji et al. 2009). The 
failure to regenerate adipose tissue at such a high density was attributed to the 
transplanted cell survival. Implanted ADSCs not only differentiate into mature 
adipocytes in vivo, but also secrete extracellular matrix (ECM) to promote its maturation 
(Tsuji et al. 2009). Stillaert et al. reported that ADSCs secrete many ECM factors that 
were able to act as inductive factors to further enhance adipogenesis in vivo (Stillaert et 
al. 2007).  
Hence the objectives of this chapter are in line with current demands of 











3.2 MATERIALS AND METHODS 
3.2.1 Design and fabrication of the bioscaffold 
We designed a three dimensional scaffold with interconnecting microchannels as 
conduits to promote tissue regeneration. Using 100 wt% poly-ε-caprolactone, PCL 
(Sigma-Aldrich Corp., St. Louis, MO); molecular weight ~65000, we fabricated the 
scaffold using a bioplotter (EnvisionTec, Gladbeck, Germany). The material pellets are 
first melted at 120°C and then the scaffold is bioprinted layer-by-layer in a cylindrical 
shape of dimension 5 mm diameter and 3 mm height. Interlaid strands had diameters of 
250-300 μm and interconnecting microchannels had a diameter of 400-500 μm. This 
overall dimension is far greater than the capacity for diffusion exchange of regenerating 
tissues, which is about 200 μm (Jain et al. 2005). The scaffolds were sterilized in an 
Ethylene Oxide (ETO) sterilizer (Anprolene AN74i, Fisher Scientific, Pittsburgh, PA) 
using a 12 hr cycle. On the day of the experiment, the scaffolds were prewetted by 
rinsing them in three cycles of PBS for 20 minutes each.  
 
3.2.2 Treatment of hADSCs with adipogenic supplements 
For cell-seeded scaffold experiments, hADSCs were cultured separately in control, 
adipogenic medium (ADM) and ADM containing 2 µM of Pyrintegrin for 2 weeks. The 





per week. On the day of the implantation, the cells were trypsinized, counted and 
seeded at a density of 10 X 106 cells/mL per scaffold by mixing the cells with 3 mg/mL 
Collagen Type I solution (10.12 mg/mL concentration, BD Bioscience, Sparks, MD). The 
scaffold is first kept in a mold, an eppendorf cap, that perfectly fits the scaffold size, and 
then this cell-collagen solution is gently pipetted within the scaffold.  The solution is 
then allowed to crosslink for 1 h at 37°C without additional cross-linker before 
implanting the scaffold in vivo. The scaffold with only collagen solution and no cells 
represents “Scaffold” group, scaffold with cells treated with control medium and mixed 
with collagen solution represents “Scaffold + cells” group, scaffold with cells treated 
with ADM mixed with collagen solution represents “Scaffold + ADM treated cells” 
group and scaffold with cells treated with ADM and Pyrintegrin mixed with collagen 
solution represents “Scaffold + ADM + Ptn treated cells” group. Our sample size per 
group was 6.  
 
3.2.3 In vivo subcutaneous scaffold implantation 
We received Institutional Animal Care and Use Committee approval to use athymic 
nude male mice (aged 7-8 weeks; Harlan, Indianapolis, IN, USA). These mice are severe 
combined immunodeficient (SCID) mice; hence there is no immune rejection of the 
transplanted human cells. On the day of the surgery, the mice were anaesthetized with 





maintained at 1-3% isoflurane throughout the experiment. After positioning the mice, 
the skin is first sterilized with 70% Ethanol and then by wiping with Betadine surgical 
scrub and Povidone-Iodine solution (Fisher Scientific, Pittsburg, PA). Using a fine 
dissecting scissor, a small cut (2-2.5 cm long) is made. All constructs were implanted in 
the subcutaneous pockets in the dorsum of mice prepared by blunt dissection. Four 
scaffolds are implanted in each mice; two on either side of the back. The skin is sutured 
back using a 4-0 P-3 vicryl coated undyed braided suture (Ethicon, Somerville, NJ). All 
the mice received an intraperitoneal (IP) injection of Rimadyl (5 mg/kg, Pfizer, New 
York, NY) post-surgery. The implants were extracted by euthanizing the animal with 
CO2 asphyxiation.  
 
3.2.4 Pyrintegrin infusion within the scaffold 
A 3 mg/mL neutralized collagen type I solution was made based on manufacturer’s 
protocol. Pyrintegrin (Ptn) at a dose of 10 µg/mL was mixed in this collagen solution. 
Ptn-adsorbed or Ptn-free collagen solution was infused completely into all the 
microchannels of the bioscaffold by pipetting approximately 20 µL of the solution 
several times. The solution is then allowed to crosslink for 1 h at 37°C without 
additional cross-linker before implanting in vivo. The scaffold with only collagen 
solution represents “Scaffold” group, and scaffold with Pyrintegrin mixed with collagen 





3.2.5 In vivo fat pad scaffold implantation 
We received Institutional Animal Care and Use Committee approval to use C57BL/6 
male mice (aged 10-11 weeks, weight 15-25 gms; Harlan, Indianapolis, IN, USA). These 
mice are susceptible to diet-induced obesity (DIO); hence they were kept on adjusted 
irradiated calories diet (60/Fat) (Harlan), with food change once every week. After 
about 6 weeks on this diet, the mice gain about 10 -15 gms of weight. On the day of the 
surgery, the mice were anaesthetized with 3–5% isoflurane (Fisher Scientific, Pittsburg, 
PA) for 5 minutes and maintained at 1-3% isoflurane throughout the experiment. After 
positioning the mice, the skin is first sterilized with 70% Ethanol and then by wiping 
with Betadine surgical scrub and Povidone-Iodine solution (Fisher Scientific, Pittsburg, 
PA). Using a fine dissecting scissor, a small cut (1-1.5 cm long) is made just about the 
upper segment of the hind limbs on both the sides in order to expose the inguinal fat 
pads.  A small pocket is made in this fat pad by making a cut big enough for the 
scaffold to be completely surrounded by fat tissue. Two scaffolds are implanted in each 
mice; one per fat pad. The skin is sutured back using a 4-0 P-3 vicryl coated undyed 
braided suture (Ethicon, Somerville, NJ). All the mice received an intraperitoneal (IP) 
injection of Rimadyl (5 mg/kg) post-surgery. The mice were kept on this diet 
throughout the experiment time period of 4 wks. The implants were extracted by 






3.2.6 Histological analysis 
After a total of 4 weeks in vivo implantation, the constructs were extracted and 
embedded in optimal cutting temperature (O.C.T.) medium (Fisher Scientific, 
Pittsburgh, PA) in cryomolds and then freezed in isopentane (Fisher Scientific, 
Pittsburgh, PA) pre-cooled in liquid nitrogen. The frozen blocks were stored at -80° C 
and shipped on dry ice for cryosectioning. Using a cryostat machine, 8 μm sections 
were cut and stained with Oil Red O and haematoxylin (Histoserv, Germantown, MD). 
The sections were then visualized under a light inverted microscope. 
 
3.2.7 Immunohistochemistry 
Immunohistochemistry for detection of human cells was performed using the antibody 
mouse anti-human nuclei (HNA) (Millipore™, Billerica, MA). Briefly, frozen sections 
were fixated in 4% paraformaldehyde solution (Fisher Scientific, Pittsburgh, PA) at 
room temperature for 15 min and briefly washed with PBS three times for 5 mins each. 
The section is then treated with 0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in 
PBS for 10 min, washed in PBS three times for 5 mins each and then blocked in Licor 
Odyssey Blocking buffer (Licor Biosciences, Lincoln, Nebraska) for 90 min. Next, 
samples were incubated with primary antibody anti-human nuclei diluted in Odyssey 
Blocking buffer (1:100), and incubated for 24 h at 4° C. Thereafter, the samples were 





mins each. The sections were incubated at room temperature for 1 h in secondary 
antibody Alexa Fluor 488 (Invitrogen, Carlsbad, USA) diluted in Odyssey Blocking 
buffer (1:250) and rinsed in Tween washing solution three times for 5 mins each. The 
coverslip was mounted by adding few drops of Vectashield Hardset mounting medium 
with DAPI (VectorLabs, Burlingame, CA). The sections were then visualized using an 
upright microscope and FITC filter.  
 
3.2.8 RNA extraction and reverse transcription polymerase chain reaction 
Total RNA was extracted from harvested in vivo constructs (n=3), using PureLink RNA 
Mini kit. The constructs were chopped into many pieces using a sterile surgical blade 
and incubated in 1.5 mL microcentrifuge tubes containing 0.6 mL of Lysis reagent for 30 
mins. Reverse transcription (RT) and polymerase chain reaction (PCR) were performed 
as described in Chapter 2. For assessing expression of adipogenic target genes, human 
PPARγ and mouse PPARγ (Mm01184322_m1), gene-specific FAM dye tagged primers 
were used. The endogenous house-keeping human GAPDH and mouse GAPDH 
(Mm99999915_g1) gene-specific FAM dye tagged primer was used to normalize 









All surgical procedures were uneventful. The C57BL/6 and SCID mice tolerated the in 
vivo implantation procedures well, without major complications. All results described 
below were consistent among all samples in the same category. 
 
3.3.1 De novo formation of adipose tissue by Pyrintegrin treatment cells 
Histological analyses demonstrated de novo formation of adipose tissue in the PCL 
constructs encapsulating adipogenic medium-treated hADSCs after 4 weeks of in vivo 
implantation in the dorsum of SCID mice. Both Scaffold + ADM treated cells (Figure 3-
1C, C1) and Scaffold + ADM + Ptn treated cells (Figure 3-1D, D1) showed positive oil 
red O staining as evident by small lipid droplets (white arrowheads) relative to the 
Scaffold + cells (Figure 3-1B, B1) or Scaffold (Figure 3-1A, A1) group. Only Scaffold + 
ADM + Ptn treated cells group had mature fat cells as evident by unilocular large lipid 
droplets (black arrowheads) in Figure 3-1D1. This means that Pyrintegrin treatment 
forms better adipose tissue in vivo. In addition, all the groups including Scaffold group 






Figure 3‐1: In vivo adipogenesis induced by tissue-engineered PCL constructs 
encapsulating human adipose derived stem cells (hADSCs) derived adipogenic cells. 





in control medium, Scaffold + cells (B and B1), scaffold encapsulating hADSCs treated 
with ADM, Scaffold + ADM treated cells (C and C1), and scaffold encapsulating 
hADSCs treated with ADM containing 2 µM of Pyrintegrin, Scaffold + ADM + Ptn 
treated cells (D and D1) implanted in the dorsum of immunodeficient mice for 4 weeks. 
Scaffold and Scaffold + cells group demonstrate no fat deposition as evident by negative 
reaction to Oil Red O staining. On the other hand, Scaffold + ADM and Scaffold + ADM 
+ Ptn treated group exhibited positive oil red O staining as evident by small lipid 
droplets (white arrowheads). Of all the groups, Scaffold + ADM + Ptn treated group 
formed a better adipogenic tissue than any other group as evidenced by unilocular fat 
droplets (black arrowheads), characteristic of mature fat cells.  All the implanted 
constructs exhibit characteristic mouse host cell invasion. PCL scaffold strand is also 












3.3.2 Detection of human adipocyte specific gene in scaffolds 
The adipocyte-specific human PPARγ gene was positively expressed in the Scaffold + 
cells, Scaffold + ADM treated cells, and Scaffold + ADM + Ptn treated cells group as seen 
in Figure 3-2. Scaffold + ADM + Ptn treated cells group showed the highest expression 
of human PPARγ gene expression than any other group, further confirming that 
Pyrintegrin treatment forms better adipose tissue in vivo. The RT-PCR experiments were 













Figure 3‐2: RT-PCR analysis showing expression of human and mouse adipocyte-
specific gene PPARγ.  The constructs Scaffold (A), scaffold encapsulating hADSCs 







with ADM, Scaffold + ADM treated cells (C), and scaffold encapsulating hADSCs 
treated with ADM containing 2 µM of Pyrintegrin, Scaffold + ADM + Ptn treated cells 
(D) were harvested from the dorsum of immunodeficient mice after 4 weeks. Of all the 
groups, Scaffold + ADM + Ptn treated group showed higher expression of human 
PPARγ gene than any other groups tested. All the implanted constructs exhibit 



















3.3.3 Detection of transplanted human cells in scaffolds 
Human nuclear staining positive cells were present in the Scaffold + cells, Scaffold + 
ADM treated cells, and Scaffold + ADM + Ptn treated cells group as seen in Figure 3-3. 
Positive staining was detected in 3/3 scaffolds at the investigated time-point after 
transplantation. Blue staining represents the nucleus of all the cells present in the 
scaffold whereas green staining represents the nucleus of the transplanted human cells. 











Figure 3‐3: Human Nuclear staining (HNA) of in vivo implanted constructs. 
Representative images of Scaffold (A), scaffold encapsulating hADSCs treated in control 
medium, Scaffold+cells (B), scaffold encapsulating hADSCs treated with ADM, 
Scaffold+ADM treated cells (C), and scaffold encapsulating hADSCs treated with ADM 
containing 2 µM of Pyrintegrin, Scaffold+ADM+Ptn treated cells (D) implanted in the 
dorsum of immunodeficient mice for 4 weeks. Positive human nuclear staining was 
observed in all the constructs except Scaffold group as evident by green fluoresce, 
whereas blue fluoresce represents DAPI staining that stains the nucleus of all the cells, 







3.3.4 De novo formation of adipose tissue in Pyrintegrin infused scaffold 
Histological analyses demonstrated de novo formation of adipose tissue in the 
Scaffold+Ptn construct after 4 weeks of in vivo implantation in the fat pad of mice, as 
shown in Figure 3-4. Only Scaffold+Ptn group had mature fat cells as evident by 
unilocular large lipid droplets (Figure 3-4C, white arrowheads). Scaffold group showed 
lack of any lipid staining (Figure 3-4B). This means that Pyrintegrin treatment forms 
better adipose tissue in vivo. In addition, all the groups showed signs of host fibroblast 











Figure 3‐4: In vivo adipogenesis induced by tissue-engineered PCL constructs infused 
with collagen gel with or without Pyrintegrin. (A) Scaffold is implanted within the fat 
pad of C57BL/6 mice. Representative images of Scaffold (B) and scaffold encapsulating 
Pyrintegrin, Scaffold + Ptn (C) implanted in the fat pad of C57BL/6 mice for 4 weeks. 
Scaffold + Ptn group formed a better adipogenic tissue than Scaffold group as exhibited 
by positive oil red O staining (white arrowheads). PCL scaffold strand is also stained 










Studies of autologous fat transplantation in certain anatomical locations of human body 
have shown occurrence of variable amount of transplanted fat resorption, with a 
volume reduction ranging from 20 to 75% (Carpaneda and Ribeiro 1993, Horl, Feller 
and Biemer 1991). Hence for reconstruction purposes, there is a demand of tissue 
engineered construct to achieve the desired result. Also large-scale tissue engineering 
constructs fail due to limited nutrient perfusion and mass transport limitations, 
especially oxygen diffusion. This restricts the construct size to smaller than clinically 
relevant dimensions and its ability for in vivo application. The volume and shape 
retention of de novo tissue engineered adipogenic constructs is a key property necessary 
in demonstrating the potential therapeutic value of this approach, in consideration of 
shape and dimension requirements associated with soft tissue augmentation and 
reconstruction. The goal of this work was to develop a modular approach to tissue 
engineering, where scaffold size, transport and nutrient issues do not hinder the 
outcome. For enhancing oxygen and nutrient transport, a channelized scaffold was 
developed for our studies. While most of the previously tested materials have failed to 
maintain their shape in vivo, a need for a biomaterial that does not lose its dimensions 
before the tissue regenerates is mandatory. We tested Alginate, Extracel, Hyaluronan 
modified gel, Fibrin, and bioplotted poly D,L-lactic-co-glycolic acid (PLGA) for 





or without cell seeding in vivo. None of these materials demonstrated a therapeutic 
potential; most of them (Extracel, Hyaluronic modified gel and Fibrin) failed to 
maintain their shape for the tested 4 weeks, while we observed a highly necrotic tissue 
within Alginate scaffold (data not shown).  Some of the previous works have indicated 
that a short-term in vitro adipogenic differentiation results in a better ectopic adipose 
tissue formation; indicating that in vitro stimulation to commit hADSCs into adipogenic 
lineages might be necessary for successful outcome of fat formation (Hong et al. 2006, 
Alhadlaq et al. 2005). The heat process applied to bioplot PLGA scaffold induced 
considerable thermal degradation releasing acidic by-products (Shim et al. 2010); hence 
it did not allow cell survival (data not shown).  Also it has been recently shown that 
nanofibrous PLGA based scaffolds are capable of supporting cellular viability, 
attachment, and proliferation during in vitro culture (Li and Lazar 2002); however, these 
matrices undergo extensive polymeric degradation in vivo leading to a compromised 
three-dimensional architecture. Because of our findings, we decided to use previously 
tested biomaterial scaffold, PCL, which has been shown to promote cell attachment, 
survival and proliferation (Lee et al. 2010, Li et al. 2005). As expected, PCL scaffold 
exhibited no change in structural integrity or three-dimensional architecture after in vivo 
extraction. Only Pyrintegrin treated cell-seeded construct developed into a better 
adipose-like tissue than Ptn-free treated cell-seeded construct as confirmed by PPARγ 





of differentiated cells. Our findings demonstrates that our scaffold material design 
encapsulating human adipose derived stem cell (hADSC)-derived adipogenic cells 
mixed with collagen gel retained the transplanted cells even after 4 weeks as shown by 
positive human nuclear staining (Figure 3-4) in all the tested groups. The number of 
positive human cells after 4 week implantation within the scaffold is very less 
compared to the initial seeding density. This can be attributed to lack of vascularization 
within the scaffold that is very important for the transplanted cell survival.  
 Hence, we also tested the capability of Pyrintegrin drug to promote de novo 
formation of adipose tissue within the scaffold implanted in fat pad. Only Pyrintegrin 
adsorbed scaffold showed positive lipid stain than Ptn-free scaffold.  Taken together, all 
of the results suggest that proliferation and differentiation of adipose precursor cells 
can be promoted depending on their microenvironment. It is likely that Pyrintegrin 
increases the number of preadipocytes and the rate of adipocyte differentiation, 











CHAPTER 4. SIGNALING MECHANISM OF 
PYRINTEGRIN 
4.1 INTRODUCTION 
Osteoporosis and obesity have become more prevalent in last couple of decades. Both 
are major health problems and are associated with body composition. Clinically age-
associated osteoporosis is associated with an increase in bone mass reduction and an 
accumulation of adipose tissue in bone marrow (Pei and Tontonoz 2004). On the other 
hand, obesity causes an increase in bone mass due to greater mechanical loading on 
bone imposed by excess body fat (Zhao et al. 2007). Other bone associated abnormalities 
where stem cells commit their fate towards adipogenic lineage are as follows: an 
increase in the bone marrow fat associated with aging (Yeung et al. 2005), the 
nutritional defect in anorexia nervosa (Abella et al. 2002) and thiazolidinedione drug 
injection induced bone fragility (Grey 2008). Bone and fat tissue are composed of 
osteoblasts and adipocytes, respectively, both of which are derived from mesenchymal 
stem cells (MSCs) (Rosen 2008, Rosen and Klibanski 2009). Furthermore, the 
differentiation of MSCs into osteogenic and adipogenic lineages is mutually exclusive 
(Zhao et al. 2007). An imbalance in the homeostasis between MSC osteoblast and 
adipocyte differentiation is associated with various diseases (Surani, Hayashi and 





As mentioned in Chapter 2, osteogenesis is regulated by several transcription factors 
such as RUNX2 and Osterix (Blair et al. 2002, Wagner and Karsenty 2001) whereas 
adipogenesis is regulated by PPARγ and C/EBPα. Overexpression of RUNX2 promotes 
differentiation of MSCs into osteoblasts (Ducy et al. 1997) whereas, forced expression of 
PPARγ2 is sufficient to induce differentiation of fibroblasts into adipocytes (Tontonoz, 
Hu and Spiegelman 1994b), and no known factors are able to stimulate adipogenesis in 
the absence of PPARγ2. Bone morphogenetic proteins (BMPs) promote the 
differentiation of osteoprogenitor cells, and also induce osteogenesis in human bone 
marrow stromal cells (MSC) (Friedman, Long and Hankenson 2006, Knippenberg et al. 
2006). 
 Bone morphogenic proteins (BMPs) are key regulators of gastrulation, formation 
of mesoderm layer, organogenesis, gametogenesis, endochondral bone formation and of 
fates of multipotent cell populations (Zhao 2003, Yu et al. 2008). BMP signals not only 
play a critical role in physiology but also in pathological diseases. BMP signals have 
been implicated in primary pulmonary hypertension, hereditary hemorrhagic 
telangiectasia (HHT), fibrodysplasia ossificans progressive (FOP) and juvenile 
polyposis syndrome (JPS) (Waite and Eng 2003, Papanikolaou et al. 2004, Shore et al. 
2006). The BMP signaling family belongs to a diverse subset of the transforming growth 
factor β (TGF-β) superfamily (Sebald et al. 2004). Several distinct BMP receptors 





identified. Over 20 known BMP ligands have been identified (Yu et al. 2008). These 
dimeric ligands facilitate the formation of receptor heteromers. Upon ligand binding, 
constitutively active Type II receptor serine/threonine kinases phosphorylate Type I 
receptor serine/threonine kinases (Fujii et al. 1999). Although both Type I and Type II 
receptors can bind BMP ligand, their affinity for BMP is relatively low unless both 
receptors are present. Optimal binding of BMP ligand occurs in the presence of both 
Type I and II BMP receptors (Walker and Wright 2002). Type I receptors are the main 
effector component of the ligand-receptor complexes since they activate downstream 
intracellular messengers (Walker and Wright 2002). Next the activated type I receptors 
phosphorylate BMP-responsive SMAD effectors (SMAD1, SMAD5 and SMAD8) to 
facilitate translocation into the cell nucleus in complex with SMAD4, a co-SMAD that 
also facilitates TGF signaling (Yu et al. 2008). In addition, BMP signals can activate 
intracellular effectors such as mitogen-activated protein kinase (MAPK) p38 in a 
SMAD-independent manner (Nohe et al. 2004).  Treatment of mesenchymal bone 
marrow stem cells with BMP-2 ligand causes an increase in gene expression of type I 








Figure 4-1: Schematic drawing showing the cellular mechanisms of BMP-induced 
osteoinduction in a mesenchymal bone marrow stem cell. 1 = Type I and Type II BMP 
homodimer receptors exist independently in the cell membrane.  2 = Upon activation by 
BMP ligand, Type II receptors phosphorylate Type I receptors. 3 = Phosphorylated Type 
I BMP receptors activate the intracellular messengers (SMADs). 4 = Activated SMADs 
localize across the nuclear membrane after association with activated Smad-4, a critical 
cofactor. 5 = Once within the nucleus, SMAD proteins induce specific gene expression. 







4.2 Materials and methods  
4.2.1 Cell culture  
Human adipose derived stem cells (hADSCs) were isolated, expanded and cultured as 
described in Section 2.2.1. NIH/3T3 cells were purchased commercially from ATCC 
(Manassas, VA). The complete growth medium for culturing this cell line was prepared 
using Dulbecco's Modified Eagle's Medium (DMEM) containing 10% bovine calf serum 
and 1% antibiotics. The cells were cultured as per ATCC guidelines.  
 
4.2.2 Multi-lineage differentiation  
Human ADSCs were differentiated into adipogenic and osteogenic linage as per our 
description in Section 2.2.2.  
 
4.2.3 Human PPARγ Reporter Assay Study 
To evaluate the potential of Pyrintegrin as a PPARγ agonist, a PPAR Reporter assay 
study kit (Indigo Biosciences, Inc., State College, PA) that utilizes non-human 
mammalian cells engineered to express human PPARγ activated receptors was used. 
These reporter cells incorporate a responsive luciferase reporter gene and quantifying 
expressed luciferase activity provides a sensitive detection of PPARγ activity in the 





immediately treated with Rosiglitazone (positive control) and different doses of Ptn 
(experimental group). Following an overnight incubation at 37° C, the treatment 
medium is discarded and 100 µl of luciferase detection reagent (LDR) is added. 
Following the addition of LDR, the plate is incubated at room temperature for 15 mins 
and the intensity of light emitted from each sample well is quantified using a plate-
reading luminometer.  
 
4.2.4 Western Blot analysis for cell signaling 
For immunoblot analysis, hADSCs are grown in a 10 cm petri dish until they become 
confluent. On the day of the treatment, the cells are treated with Control, ADM, 
ADM+Ptn, and Control+Ptn medium for 1 hr and then briefly washed with ice cold PBS 
and scrapped off with an ice cold scrapper in 1 ml of ice cold PBS. The cell extract is 
collected in an ice cold eppendorf tube and briefly centrifuged at 1000 rpm for 2 mins at 
4° C. The supernatant medium is discarded and the cell pellet is mechanically 
homogenized in Nonidet-P40 (NP40) lysis buffer (50 mM Tris-HCl (pH 8), 1% NP40, 150 
mM NaCl, Phosphatase Inhibitor, Protease Inhibitor) for 20 mins. The cell extract is then 
centrifuged at 12000 rpm for 20 mins at 4° C. The supernatant is then collected in a fresh 
ice cold eppendorf tube and stored at -80° C till further use. The protein concentration is 
determined by performing a Bradford assay and using bovine serum albumin (BSA) as 





analysis, 20 µg of protein is mixed with LDS loading buffer (4X), and reducing agent 
(10X) and then denatured by heating at 70°C for 10 mins. The protein samples and the 
ladder are loaded onto 4-12% NuPAGE Novex Bis-Tris gels (Invitrogen), ran at 200 V 
for 35 mins in a Running buffer (20X) diluted in distilled water. The protein is then 
transferred onto a PVDF membrane (Biorad) at 60 V for 1 hr using 200 ml of buffer (40 
ml of Methanol, 10 ml of Transfer buffer (20X) and 150 ml of distilled water). Once the 
protein has been transferred to the membrane, the membrane is blocked using 10 mL of 
Odyssey blocking buffer (Licor Biosciences, Lincoln, Nebraska) and rocked on a shaker 
for 30 mins. The membrane is then immunoblotted overnight first with phospho-
SMAD1/5/8, SMAD1, phospho-p42/p44 MAPK (Cell Signaling) or β-Actin (Santa Cruz 
Biotechnology) primary antibodies, washed several times with washing buffer (150 mM 
NaCl, 0.05% Tween-20, 50 mM Tris HCl, the pH is adjusted to 7.6 with HCl)and then 
incubated for 1 hr with ALP conjugated secondary antibodies. After secondary antibody 
labeling, the membrane is washed again several times and the protein bands are then 
visualized using 1-Step NBT/BC1P (ALP substrate buffer). 
 
4.2.5 Immunoblot analysis of BMP and TGF-β–responsive SMAD 
phosphorylation 
For SMAD signaling pathway analysis, hADSCs were plated at a density of 5 X 104 cm2 





used. The cells were allowed to become 90-100% confluent. Upon reaching confluency, 
the cells were serum starved overnight by incubating the cells in growth medium 
containing 2% FBS. The cells are treated with growth medium containing 2% FBS 
(Control), Control medium containing BMP4 30 ng/mL, and Control medium 
containing BMP4 and varying doses of Pyrintegrin (0.2, 0.5, 1, 2, 5, 10 and 20 µM) for 1 
h. After the incubation period, the protein is extracted using the same procedure as 
described in Section 4.2.4. Cell extracts were mechanically homogenized in Nonidet-
P40 (NP40) lysis buffer (50 mM Tris-HCl (pH 8), 1% NP40, 150 mM NaCl, Phosphatase 
Inhibitor, Protease Inhibitor), separated by NuPAGE Bis-Tris gels (Invitrogen), 
immunoblotted with anti-phospho-SMAD1/5, anti-SMAD1, anti-phospho-SMAD2,  
anti-phospho-p38 MAPK, anti-p38 MAPK (Cell Signaling) or anti-β-Actin (Santa Cruz 
Biotechnology) primary antibodies, and Alexa Flour 680 goat anti-rabbit IgG or Alexa 
Flour 680 goat anti-mouse IgG (Invitrogen) and visualized using Odyssey Infrared 
Imager  (Licor Biosciences, Lincoln, Nebraska).  
 
4.2.6 Real Time‐Polymerase Chain Reaction (RT-PCR) analysis 
For RT-PCR, passage P7 hADSCs were seeded at a density of 5 × 104 cells/cm2 on a 24 
well tissue culture plate. The total RNA was isolated, quantified, reverse transcribed 
and amplified as described in Section 2.2.4. For assessing expression of human 





and Transcription factor Sp7 (Cba1, Hs01866874_s1) gene-specific FAM dye tagged 
primers were used. For assessing expression of human adipogenic target genes, PPARγ 
and C/EBPα gene-specific FAM dye tagged primers were used. The endogenous house-
keeping GAPDH gene-specific FAM dye tagged primer was used to normalize gene 
expression and relative quantification was performed using Comparative ΔΔCt method 
and Standard reagents. 
 
4.2.7 Alizarin Red S staining  
After removing the culture medium from the wells, human ADSC cultures were 
washed with Phosphate Buffer saline (PBS, Sigma-Aldrich, St. Louis, MO), fixed in 
warmed 4% paraformaldehyde solution (Fisher Scientific, Pittsburgh, PA) for 10-30 min 
at room temperature. After removing the fixative, the cells were gently washed twice 
with PBS and then stained with Alizarin Red S stain (Sigma) for 5 minutes as per 
manufacturer’s protocol. Once the dye is removed, the cells are washed with water and 
imaged using an inverted microscope and a camera controlled by image acquisition 
software (Leica LAS 3.0). The plates were scanned using a HP Scanjet 8390 scanner 
(Hewlett Packard Development Company, Palo Alto, CA).  
 
4.2.8 Lipid staining  





well tissue culture plate. After treating the cells for the experimental time period of 3 
weeks, the culture medium is removed from the wells and human ADSC cultures were 
washed, stained and visualized as described in Section 2.2.4.   
 
4.2.9 Dexamethasone dose treatment analysis 
Passage P7 hADSCs were seeded at a density of 5 × 104 cells/cm2 on a 24 well tissue 
culture plate. After treating the cells with control medium containing 2 µM of 
Pyrintegrin and different doses of Dexamethasone (Dex, 0.1-10 µM) for the 
experimental time period of 3 weeks, the culture medium is removed from the wells 
and human ADSC cultures were washed, stained for lipid visualization as described in 
Section 2.2.4.   
 
4.2.10 Statistics 
After confirmation of normal data distribution, 1-way ANOVA with post-hoc 










4.3.1 Is Pyrintegrin a PPARγ agonist? 
Since the treatment of Pyrintegrin directs the stem cell towards adipogenic lineage, we 
wanted to test the role of Ptn as a PPARγ agonist. To test this, we aimed at quantifying 
the functional activity exerted by Ptn against PPARγ by performing a human PPARγ 
receptor reporter assay study. By testing the PPARγ transfected reporter cells against a 
known PPARγ agonist, Rosiglitazone as a positive control, we evaluated the dose effect 
of Ptn in up regulating PPARγ luciferase activity. Ptn failed to increase PPARγ activity 
as shown in Figure 4-2, thereby confirming that Ptn is not a PPARγ agonist and that it 











Figure 4‐2: Human PPARγ luciferase reporter assay system. Rosiglitazone, a known 
PPARγ agonist, significantly up regulated PPARγ luciferase activity at 0.5 µM 
concentration (positive control).  Whereas, culture Pyrintegrin failed to up regulate 
PPARγ luciferase activity at any of the tested concentration. Hence, Pyrintegrin is not a 












4.3.2 Signaling mechanism of Pyrintegrin 
In an effort to understand the possible mechanism of Ptn effect, we tested its role on any 
of the known signaling pathways involved in adipogenic differentiation. At 80-90% 
confluency, the cells were treated with control, ADM, ADM+Ptn and control+Ptn group 
for 1 h. We found that Ptn exerts its effect by actually targeting transforming growth 
factor (TGF) superfamily. Ptn down regulates the phosphorylation of Smad1/5/8, a 
downstream target of bone morphogenic protein (BMP) receptors as shown in Figure 4-
3. Treatment with Ptn does not inhibit phosphorylation of Smad2, a downstream target 























Figure 4‐3: Pyrintegrin inhibits BMP signaling pathway. Phosphorylation of SMAD1/5/8 
(a) and p44/42 MAPK (b) in hADSCs detected by immunoblot after pretreatment with 
Control, ADM, ADM+Ptn and Control+Ptn medium for 1 hr (a).  Equivalent protein 








4.3.3 Pyrintegrin inhibits SMAD-dependent BMP signals 
To further confirm the effect of Pyrintegrin, its effect on BMP signaling was tested in 
vitro. At 100% confluency, the cells were treated with control, BMP4, BMP4+Ptn (0.2-20 
µM) for 1 h. In response to BMP ligand, hADSCs showed SMAD1/5 activation, whereas 
Pyrintegrin inhibited BMP4-induced phosphorylation of BMP responsive SMADs in a 
dose-dependent manner as shown in Figure 4-4a. The unique ability of Pyrintegrin to 
functionally activate MAPK p38 in NIH/3T3 cells only at higher concentrations (5-20 
µM) is evident by increase in phosphorylation of MAPK p38 as shown in Figure 4-4b.  
MAPK p38 has been shown to be preferentially activated by environmental stresses and 
inflammatory cytokines. This ability of Pyrintegrin to induce stress as well as activation 
of MAPKs may play an important role in its effect on cell growth, maturation and 
differentiation. Pyrintegrin did not inhibit SMAD2 activation by TGF-β1 at 
concentrations equal to or greater than those that were inhibitory to BMP signaling as 




























Figure 4‐4: Pyrintegrin inhibits BMP-mediated activation of SMAD. (a) Phosphorylation 
of SMAD1/5 in hADSCs detected by immunoblot after treatment with BMP4 and 
Pyrintergin for 1 hr. Equivalent protein loading was confirmed by detection of total 
SMAD1 and β-Actin. (b) Phosphorylation of SMAD2 in hADSCs after treatment with 
TGFβ1 and Pyrintegrin for 1 hr. Treatment with Pyrintegrin (0.1-20 µM) did not inhibit 
TGFβ1-mediated activation of SMAD2.  (c) Phosphorylation of MAPK p38 in NIH/3T3 










4.3.4 Pyrintegrin inhibits osteogenic gene expression in osteogenic 
differentiated hADSCs 
The ability of Pyrintegrin to block BMP-mediated signaling suggested that Ptn might 
play an inhibitory role in osteoblast differentiation. At 80-90% confluency, hADSCs 
were treated for 21 days with control medium (Control), osteogenic differentiation 
medium (ODM), and ODM containing 2 µM of Pyrintegrin (ODM+Ptn). During the 21 
days of culture, ODM+Ptn group showed a significant down regulation in osteogenic 
specific markers, RunX2 and Sp7, compared to ODM group as shown in Figure 4-5a, b. 
On the other hand, ODM+Ptn group showed a higher up regulation of adipogenic 




































Figure 4‐5: Pyrintegrin inhibits osteogenic specific genes in osteogenic-mediated 
differentiation of hADSCs. Relative quantification of human osteogenic RunX2 (a) and 
Osx (b) and adipogenic markers, PPARγ (c) and CEBPα (d) gene expression in hADSCs 







(ODM+Ptn). ODM+Ptn showed a significant down regulation in osteogenic gene 
expression and a significant up regulation of adipogenic specific genes than ODM 






















4.3.5 Pyrintegrin inhibits osteoblast differentiation 
The ability of Pyrintegrin to induce adipogenic genes and inhibit osteogenic genes in 
osteogenic differentiating medium suggested that Ptn might inhibit osteoblast 
differentiation. To test this, we utilized Alizarin Red S staining that stains mineral 
deposits (a marker of osteogenic differentiation). P6-7 hADSCs isolated from the 
subcutaneous abdominal human fat tissue were plated at a density of 5 X 103 cells per 
cm2. The cells are culture expanded in a 24 well tissue culture plate. At 80-90% 
confluency, hADSCs were induced to differentiate for 21 days in Control medium 
(Control), osteogenic differentiation medium (ODM), ODM containing 2 µM of 
Pyrintegrin (ODM+Ptn). The addition of Ptn to the ODM significantly inhibited the 
production of mineralized nodules as compared to ODM alone treated group as shown 
in Figure 4-6. A scanning of the whole plate using a scanner shows marked decrease in 









Figure 4‐6: Pyrintegrin inhibits osteoblast differentiation of hADSCs in vitro. Human 
ADSCs were induced to differentiate for 21 days in osteogenic differentiation medium 
(ODM) (A and A1), ODM containing 2 µM of Pyrintegrin (ODM+Ptn) (B and B1). The 
addition of Ptn to the osteogenic differentiation medium significantly inhibited the 
production of mineralized nodules as seen by less Alizarin Red S staining compared to 






4.3.6 Pyrintegrin promotes lipid accumulation in osteogenic 
differentiated hADSCs 
At 80-90% confluency, hADSCs were treated for 21 days with ODM, ODM+Ptn and 
control medium containing 2 µM of Pyrintegrin (Control+Ptn). Only ODM+Ptn group 
had visible lipid droplets at any given time point as shown in Figure 4-7. Both ODM 
and Control+Ptn group did not have any lipid accumulation during the entire 
experimental period. Between ADM and ODM medium, the only common ingredient is 
Dexamethasone, hence we concluded that presence of Dex might be essential for lipid 








Figure 4‐7: Pyrintegrin promotes lipid formation in osteogenic-mediated differentiation 
of hADSCs. Fluorescent red lipid staining in hADSCs culture treated with ODM (A, D 
and G), ODM containing 2 µM of Pyrintegrin (ODM+Ptn) (B, E and H) and control 
medium containing 2 µM of Pyrintegrin (Ptn) (C, F and I). Only ODM+Ptn group 
showed an accumulation of lipids during the tested 7 (B), 14 (E) and 21 (H) days. Scale 






4.3.7 Dexamethasone and Pyrintegrin combination promotes lipid 
accumulation in osteogenic differentiated hADSCs 
To test whether, Dexamethasone concentration has any effect on lipid accumulation in 
Pyrintegrin treated group, at 80-90% confluency, hADSCs were treated for 21 days with 
Control medium containing Pyrintegrin and different doses of Dex (0.1, 1 and 10 µM). 
We found that there was no significant difference in the lipid accumulation between 










Figure 4‐8: Presence of Dexamethasone (Dex) is necessary for Pyrintegrin induced lipid 
formation. hADSCs culture are treated with 2 µM of Pyrintegrin and varying dose of 
Dex 0.1 µM (A, A1 and A2), 1 µM (B, B1 and B2) and 10 µM (C, C1 and C2) for 21 days. 
Presence of Dex and not its concentration is important for lipid accumulation in Ptn 









By comparing its effect with a known PPARγ agonist, Rosiglitazone, we showed that 
Ptn is not a PPARγ agonist. We found that Ptn might exert its effect on adipogenic 
differentiation of hADSCs by inhibiting BMP signaling pathway. The control of 
mesenchymal stem cell lineage fate is critical for the regeneration and repair of tissues. 
In many of the bone pathologies, the inclination of stem cells towards adipogenic 
lineage comes at the expense of the osteogenic lineage. Both in vitro and in vivo studies 
have shown that PPARγ activation with TZDs promotes the differentiation of precursor 
cells into adipocytes and inhibits their differentiation into osteoblasts (Lecka-Czernik et 
al. 1999, Jackson and Demer 2000, Soroceanu et al. 2004). This observation correlates 
well with our finding of Pyrintegrin treatment that promotes adipogenesis while 
inhibiting osteogenesis in hADSCs. A recent clinical and biological research on 
cytokines released by adipocytes has revealed a connection between these 
adipocytokines and skeleton biology.  
 Glucocorticoids, such as Dex are potent stimulators of adipocyte differentiation 
in 3T3-L1 and TA-1 preadipocytes and of some other cell types under certain conditions 
(Chapman, Knight and Ringold 1985, Knight et al. 1987). The glucocorticoid receptor is 
a member of the nuclear hormone receptor family and upon ligand binding can directly 
activate transcription of C/EBPδ gene relevant for adipogenic differentiation.  Hence, 





The accumulation is not that robust as compared to ADM and Pyrintegrin treatment, 
which might be due to lack of Insulin in Dex and Pyrintegrin treated group.  
 Previously, in vivo inhibition of BMP signaling in experimental therapy has been 
accomplished by administration of soluble receptor extracellular domains or ligand-
specific neutralizing antibodies (Sugimoto et al. 2007), or by gene transfer of 
endogenous antagonists such as noggin or follistatin (Feeley et al. 2006, Takabe et al. 
2003).  Because all of these strategies for inhibiting BMP signaling function by 
sequestering BMP ligands, Pyrintegrin may favor the possibility of inhibiting via SMAD 
BMP signaling pathway.  
 A better understanding of diseases of energy metabolism including obesity and 
obesity-related diabetes will also result from studies of the differentiation of 
mesenchymal stem cells to adipocytes. While a cellular and biochemical basis for 
obesity has long been suspected, advancements have been slow due to a lack of model 
systems with biochemical and molecular tools for study. Recent dramatic 
breakthroughs in the molecular basis of adipogenesis have opened new avenues 
towards understanding this pathway of mesenchymal cell differentiation, although a 
human model system such as the one described here has been lacking. Since BMPs also 
regulate regeneration of mature tissues and stem cell differentiation (Qi et al. 2004, Xu 
et al. 2005), modulating BMP signaling might also prove useful for the manipulation of 





but not TGF-β or other pathways, could help elucidate the roles of BMP signaling in 
diverse physiological processes.  
 Despite the apparent selectivity of Pyrintegrin for BMP signaling, it is important 
to consider the possibility that Ptn, like all known kinase inhibitors, may affect other 
kinase targets, particularly at higher doses. Nevertheless, when using Ptn, the 
possibility of confounding effects from secondary targets needs to be considered, and if 
possible the lowest effective dose should be considered to maximize selectivity for BMP 

















CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
5.1 SUMMARY 
 This thesis explores the role of a novel small-molecule drug, Pyrintegrin both in 
vitro and in vivo. The compound was identified in a screen of compounds that facilitate 
human embryonic stem cells survival. Upon addition of Pyrintegrin to the 
differentiation culture medium, there was an up regulation in the adipogenic specific 
genes. This observation was consistent even when the cells were treated with osteogenic 
and chondrogenic lineage specific differentiation medium. The drug was potent in 
inducing adipogenic specific genes, PPARγ and C/EBPα at 2 μM concentration. 
Functional analysis involving release of adipocytokines and fatty acids in human 
adipose derived stem cells (hADSCs) treated with adipogenic differentiation medium 
revealed that Pyrintegrin significantly increased adipocytokine release of adiponectin 
and leptin and glycerol and triglyceride secretion during the tested 28 days. The 
hADSCs showed an increased expression of adipogenic specific genes when treated 
with Pyrintegrin alone. This further confirmed that the drug was directing the stem 
cells towards an adipogenic lineage. Upon further characterization, we found that 
Pyrintegrin is not a PPARγ agonist, since it failed to promote luciferase activity in 
human PPARγ reporter cells at the tested doses. Rosiglitazone, a known PPARγ agonist 





We found that Pyrintegrin up regulates adipogenic differentiation by targeting BMP 
specific pathway as evidenced by inhibition of SMAD1/5/8 phosphorylation.  
  As was discussed in Chapter 3, adipogenesis and osteogenesis are two mutually 
exclusive differentiation processes. Hence, we further investigated the role of 
Pyrintegrin in directing the stem cell fate towards osteogenesis. By treating the cells 
with the osteogenic medium in the presence of Pyrintegrin, we found that Pyrintegrin 
significantly down regulated the differentiation of the cells towards osteogenic lineage. 
This was confirmed by Alizarin Red staining that stains calcium nodules formed during 
the osteogenic differentiation. The drug was potent in inducing adipogenic specific 
genes, PPARγ and C/EBPα in human adipose derived stem cells (hADSCs) treated with 
osteogenic differentiation medium. This up regulation of adipogenic genes came at a 
cost of down regulating osteogenic genes, RunX2 and Osx for the tested 21 days. We 
also found that Pyrintegrin treated osteogenic medium group alone and not osteogenic 
medium treated group had significant amount of lipid droplet accumulation, a 
characteristic of adipocyte formation for the tested 21 days. The presence of 
glucocorticoid, Dexamethasone (Dex) was important for Pyrintegrin to promote lipid 
droplets in hADSCs. Upon increasing Dex concentration within the Pyrintegrin treated 
group, we did not see a significant difference in the amount of lipid droplets. Upon 
further analysis, we found that Pyrintegrin inhibits BMP-mediated activation of SMAD 





the differentiation potential of the stem cells. Functional selectivity for BMP signaling is 
further supported by in vitro data demonstrating that Pyrintegrin preferentially inhibits 
BMP signaling over TGFβ signaling. Pyrintegrin treatment (0.2–20 µM) did not inhibit 
TGFβ1 –mediated activation of SMAD2.  
 Next, we analyzed the potential of the drug in vivo to regenerate soft tissue. We 
fabricated a 3D PCL scaffold with channels and infused the channels with Pyrintegrin 
drug adsorbed to the collagen gel. The aim of this experiment was to see if more fat like 
cells filled the channels in the presence of Pyrintegrin drug compared to the scaffold 
infused with collagen gel only after 4 wks. We found that as the gel degrades in vivo 
slowly releasing the drug locally, more lipid-ladden adipocytes were present within the 
scaffold compared to the scaffold without drug that was infiltrated by more fibroblast 
like cells. These adipocytes stained positively for Oil Red O stain dye.  Next, we also 
tested the capability of human adipose derived stem cells treated with adipogenic 
medium for 14 days with and without Pyrintegrin drug to regenerate a better soft tissue 
in vivo. After pretreating the cells with the medium, the cells were mixed with collagen 
gel at a density of 10 M cells/mL. This gel was then infused into the channels of a 3D 
bioplotted PCL scaffold and implanted subcutaneously under the skin of a SCID mouse 
for 28 days. Upon extraction of the implant, we found that the cells pretreated with 
adipogenic medium containing Pyrintegrin drug comparatively had more adipocytes 





staining and gene expression analysis that showed higher expression of adipogenic 
markers in Pyrintegrin treated group. Here we show the functional specificity of 
Pyrintegrin by demonstrating its ability to promote more fat formation within the 






















5.2 FUTURE DIRECTIONS 
5.2.1 Pyrintegrin for treatment of obesity and diabetes  
Numerous diseases or disorders are linked to formation of excess fat in humans. 
Specially, obesity is currently a global pandemic that is associated with high rates of 
metabolic syndrome and disorders, such as Type II diabetes mellitus, cardiovascular 
disease, and some cancers.  
For obesity, the body mass index (BMI) is a reliable tool to estimate body’s fat 
based on one’s height and weight. A higher BMI (>25) is normally considered 
overweight or obese, as defined by Center for Disease Control and Prevention. An 
excess of body fat around the central and intra-abdominal depots increases the risk of 
cardiovascular disease and diabetes (Yusuf et al. 2004, Ohlson et al. 1985). In this thesis, 
we demonstrated that Pyrintegrin is a potent adipogenic stimulator in vitro and in vivo 
and that it exerts its effect by targeting BMP signaling pathway. Thus, this molecular or 
signaling pathway activated by Pyrintegrin to promote stem cell adipogenic 
differentiation could further provide us an insight in understanding disease models 
promoting fat formation. By targeting that specific signaling pathway, it might be 
possible for the adipocytes to dedifferentiate back to their precursor or stem cell stage. It 
is anticipated that key molecules or factors negating Pyrintegrin effect might be 
considered for obesity therapy. Bone morphogenetic proteins (BMPs) that belong to the 





their effects on energy metabolism (Schulz and Tseng 2009, Tobin and Celeste 2006, 
Zamani and Brown 2011, Johnen et al. 2007, Yadav et al. 2011). The TGFβ/BMP 
signaling pathway has been shown to regulate food intake and quiescence in 
Caenorhabditis elegans (You et al. 2008) and to modulate metabolism in response to 
nutrient state in Drosophila (Ballard, Jarolimova and Wharton 2010). BMP proteins can 
also produce an inflammatory response in endothelial cells that can lead to vascular 
diseases such as hypertension, and atherosclerosis. These conditions are effectively 
inhibited by treatment with the known BMP inhibitor, noggin. Because noggin is a 
protein and cannot be administered orally, screening of small molecules that could 
potently and specifically inhibit BMP action is important. Physiological tools that 
selectively inhibit BMP signaling, but not TGFβ or other pathways, could help elucidate 
the roles of BMP signaling in diverse physiological processes.  
For diabetes, Thiazolidinedione, a class of synthetic PPARγ agonists, such as 
Rosiglitazone, Pioglitazone and Troglitazone are currently used to treat Type II diabetes 
mellitus. TZDs that promote adipogenic differentiation of stem cells in vitro were found 
to enhance insulin sensitivity and lowers blood glucose levels in vivo. TZDs selectively 
stimulate PPARγ and thereby exert their effect. But they are associated with severe side 
effects such as cardiac failure, edema etc. and hence were withdrawn from the market. 
The use of PPARγ modulators should be approached with caution as PPARγ is not only 





Hence the need for indirect modulators of PPARγ, which do not cause severe side 
effects, is pivotal. It would be worthwhile to test the effect of Pyrintegrin in various 
diabetic mice models available.  
 
5.2.2 Pyrintegrin for treatment of bone disorders 
An imbalance between bone formation and bone breakdown process in a normal adult, 
leads to rheumatoid arthritis and osteoporosis. As described in Chapter 4, 
mesenchymal progenitor cells give rise to osteoblasts and adipocytes, depending on the 
signals it receives from its environment and as depicted in Figure 5-1. In disease state, 
not only bone remodeling is disturbed but also there is deposition of fat within the 
marrow (Meunier et al. 1971). Since the ligand activation of PPARγ drives the 
differentiation of multipotent mesenchymal progenitor cells towards adipocytes over 
osteoblasts (Lecka-Czernik et al. 2002, Jeon et al. 2003), targeting PPARγ might hold 
some clues to such debilitating bone diseases. It becomes worthwhile in understanding 
the various mechanisms associated with stem cell differentiation into adipocytes. Since 
Pyrintegrin promotes mesenchymal stem cell differentiation into adipocytes and 
inhibits bone formation in vitro, it might be a perfect tool in depicting the adipogenesis 
pathway. By formulating an antidote to Pyrintegrin may be required to explore the role 








Figure 5-1: Role of PPARγ pathway on osteogenesis. Bone homeostasis is maintained by 
the balance between osteoblastic bone formation and osteoclastic bone resorption. An 
imbalance in this homeostasis is associated with osteoporosis. The PPARγ pathway 
influences adipocyte differentiation from mesenchymal progenitors at the cost of 
inhibiting osteoblast differentiation. Adopted from (Pei and Tontonoz 2004). This new 
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